US20140315919A1 - Highly selective sigma receptor ligands - Google Patents
Highly selective sigma receptor ligands Download PDFInfo
- Publication number
- US20140315919A1 US20140315919A1 US14/321,100 US201414321100A US2014315919A1 US 20140315919 A1 US20140315919 A1 US 20140315919A1 US 201414321100 A US201414321100 A US 201414321100A US 2014315919 A1 US2014315919 A1 US 2014315919A1
- Authority
- US
- United States
- Prior art keywords
- optionally substituted
- alkyl
- subject
- cocaine
- nitro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 Cl=C1Clc(cccc2)c2N1CCCCC*(CC1)CCN1C1CCCCC1 Chemical compound Cl=C1Clc(cccc2)c2N1CCCCC*(CC1)CCN1C1CCCCC1 0.000 description 15
- CADFCIVZOGTRRX-UHFFFAOYSA-N CC(C)N1CCN(C2CCCCC2)CC1 Chemical compound CC(C)N1CCN(C2CCCCC2)CC1 CADFCIVZOGTRRX-UHFFFAOYSA-N 0.000 description 10
- SEWPEAQTAQNDFW-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 SEWPEAQTAQNDFW-UHFFFAOYSA-N 0.000 description 3
- QTVZKXTYXRRYBK-UHFFFAOYSA-N C1=CC=C2C(=C1)C=CN2CCCCN1CCN(C2CCCCC2)CC1 Chemical compound C1=CC=C2C(=C1)C=CN2CCCCN1CCN(C2CCCCC2)CC1 QTVZKXTYXRRYBK-UHFFFAOYSA-N 0.000 description 2
- YHNWWOUWKSLFOO-UHFFFAOYSA-N CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=C(F)C=CC=C3)CC1)C(=O)O2 Chemical compound CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=C(F)C=CC=C3)CC1)C(=O)O2 YHNWWOUWKSLFOO-UHFFFAOYSA-N 0.000 description 2
- VGDFDVKDWFJQHD-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(F)C=C2)CC1 VGDFDVKDWFJQHD-UHFFFAOYSA-N 0.000 description 2
- JBVLLCAEJVKUOD-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C([N+](=O)[O-])C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C([N+](=O)[O-])C=C2)CC1.[H]Cl.[H]Cl JBVLLCAEJVKUOD-UHFFFAOYSA-N 0.000 description 2
- MWZDRLGFCJIJTG-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 MWZDRLGFCJIJTG-UHFFFAOYSA-N 0.000 description 2
- OOUUCXHRUNDCRX-UHFFFAOYSA-N CCC(=O)C1=CC2=C(C=C1)N(CCCN1CCCCC1)C(=O)O2.CCC(=O)C1=CC2=C(C=C1)N(CCCN1CCCCC1)C(=O)S2.CCCC1=CC2=C(C=C1)N(CCCCN1CCCCC1)C(=O)S2.CCCC1=CC2=C(C=C1)N(CCN1CCCCC1)C(=O)CO2.CCCC1=CC2=C(C=C1)N(CCN1CCCCC1)C(=O)S2 Chemical compound CCC(=O)C1=CC2=C(C=C1)N(CCCN1CCCCC1)C(=O)O2.CCC(=O)C1=CC2=C(C=C1)N(CCCN1CCCCC1)C(=O)S2.CCCC1=CC2=C(C=C1)N(CCCCN1CCCCC1)C(=O)S2.CCCC1=CC2=C(C=C1)N(CCN1CCCCC1)C(=O)CO2.CCCC1=CC2=C(C=C1)N(CCN1CCCCC1)C(=O)S2 OOUUCXHRUNDCRX-UHFFFAOYSA-N 0.000 description 2
- AJWVTQCMTSENFP-UHFFFAOYSA-N CCC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CCC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl AJWVTQCMTSENFP-UHFFFAOYSA-N 0.000 description 2
- YCRPNMZPFZDGOK-WKISXKBFSA-N CCCC1=CC2=C(C=C1)N(CCCN1CCCCC1)C(=O)S2.CCCC1=CC2=C(C=C1)N(CCN1CCCCCC1)C(=O)S2.CCCC1=CC2=C(C=C1)N(CCN1C[C@@]3(C)CCC[C@@]3(C)C1)C(=O)S2.CCCCC1=CC2=C(C=C1)N(CCN1CCCCC1)C(=O)S2.O=C(C1=CC2=C(C=C1)N(CCN1CCCCC1)C(=O)S2)C1CC1 Chemical compound CCCC1=CC2=C(C=C1)N(CCCN1CCCCC1)C(=O)S2.CCCC1=CC2=C(C=C1)N(CCN1CCCCCC1)C(=O)S2.CCCC1=CC2=C(C=C1)N(CCN1C[C@@]3(C)CCC[C@@]3(C)C1)C(=O)S2.CCCCC1=CC2=C(C=C1)N(CCN1CCCCC1)C(=O)S2.O=C(C1=CC2=C(C=C1)N(CCN1CCCCC1)C(=O)S2)C1CC1 YCRPNMZPFZDGOK-WKISXKBFSA-N 0.000 description 2
- OYRXTDJDTMULAS-UHFFFAOYSA-N COC1=CC2=C(C=C1)N(CCCCN1CCC3=C(C=C(OC)C(OC)=C3)C1)C(=O)O2 Chemical compound COC1=CC2=C(C=C1)N(CCCCN1CCC3=C(C=C(OC)C(OC)=C3)C1)C(=O)O2 OYRXTDJDTMULAS-UHFFFAOYSA-N 0.000 description 2
- HDRNEAMIVJIRBJ-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C=CC3=CC=CC=C31)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C=CC3=CC=CC=C31)CC2 HDRNEAMIVJIRBJ-UHFFFAOYSA-N 0.000 description 2
- HQFUMVQMUFRCMD-UHFFFAOYSA-N O=C1N(CCCCN2CCC3(CC2)OCC2=C3C=CC=C2)C2=CC=CC=C2N1C1=CC=C(F)C=C1 Chemical compound O=C1N(CCCCN2CCC3(CC2)OCC2=C3C=CC=C2)C2=CC=CC=C2N1C1=CC=C(F)C=C1 HQFUMVQMUFRCMD-UHFFFAOYSA-N 0.000 description 2
- HJLXZSLXEIWJEV-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CC2CCC(C1)C21OCC2=C1C=CC=C2 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CC2CCC(C1)C21OCC2=C1C=CC=C2 HJLXZSLXEIWJEV-UHFFFAOYSA-N 0.000 description 2
- OBMUXGXYWUSAQQ-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C(Cl)C=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C(Cl)C=C2)CC1 OBMUXGXYWUSAQQ-UHFFFAOYSA-N 0.000 description 2
- JWHSVWAPKZRWGX-UHFFFAOYSA-N O=C1Oc(cccc2)c2N1CCCN(CC1)CCN1C1CCCCC1 Chemical compound O=C1Oc(cccc2)c2N1CCCN(CC1)CCN1C1CCCCC1 JWHSVWAPKZRWGX-UHFFFAOYSA-N 0.000 description 2
- UZTWFCZMLAYKQA-UHFFFAOYSA-N O=C1SC2=CC=CC=C2N1CCCCCCN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl Chemical compound O=C1SC2=CC=CC=C2N1CCCCCCN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl UZTWFCZMLAYKQA-UHFFFAOYSA-N 0.000 description 2
- ZACKDLLCPUTVQK-UHFFFAOYSA-N O=C1SC2=CC=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1SC2=CC=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 ZACKDLLCPUTVQK-UHFFFAOYSA-N 0.000 description 2
- OUNADMZDANCSEJ-UHFFFAOYSA-N C1=CC2=C(C=C1)OC(SCCCCN1CCN(C3CCCCC3)CC1)=N2 Chemical compound C1=CC2=C(C=C1)OC(SCCCCN1CCN(C3CCCCC3)CC1)=N2 OUNADMZDANCSEJ-UHFFFAOYSA-N 0.000 description 1
- BDFDAEFWSLVSGA-UHFFFAOYSA-N C=C(C)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(C)C=C2)CC1.[H]Cl.[H]Cl Chemical compound C=C(C)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(C)C=C2)CC1.[H]Cl.[H]Cl BDFDAEFWSLVSGA-UHFFFAOYSA-N 0.000 description 1
- YRJIBMRWYQKMLK-UHFFFAOYSA-N CC(=O)C1=CC2=C(C=C1)N(CCC(O)CN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 Chemical compound CC(=O)C1=CC2=C(C=C1)N(CCC(O)CN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 YRJIBMRWYQKMLK-UHFFFAOYSA-N 0.000 description 1
- MTCHHIDNPPFHDV-UHFFFAOYSA-N CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCC3=C(C=CC=C3)C1)C(=O)O2 Chemical compound CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCC3=C(C=CC=C3)C1)C(=O)O2 MTCHHIDNPPFHDV-UHFFFAOYSA-N 0.000 description 1
- FLBAWBZNDRPUPX-UHFFFAOYSA-N CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=C(Br)C=C(F)C=C3)CC1)C(=O)O2 Chemical compound CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=C(Br)C=C(F)C=C3)CC1)C(=O)O2 FLBAWBZNDRPUPX-UHFFFAOYSA-N 0.000 description 1
- ADLKSCRDZHOWLZ-UHFFFAOYSA-N CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=C(Cl)C(Cl)=CC=C3)CC1)C(=O)O2 Chemical compound CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=C(Cl)C(Cl)=CC=C3)CC1)C(=O)O2 ADLKSCRDZHOWLZ-UHFFFAOYSA-N 0.000 description 1
- OQEGLZOYMMYASC-UHFFFAOYSA-N CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC(F)=CC=C3)CC1)C(=O)O2 Chemical compound CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC(F)=CC=C3)CC1)C(=O)O2 OQEGLZOYMMYASC-UHFFFAOYSA-N 0.000 description 1
- JHGSSHFZEAXZJA-UHFFFAOYSA-N CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)S2.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)S2.[H]Cl.[H]Cl JHGSSHFZEAXZJA-UHFFFAOYSA-N 0.000 description 1
- DXTKWQFMIQLLCM-NSCUHMNNSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2C/C=C/CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2C/C=C/CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl DXTKWQFMIQLLCM-NSCUHMNNSA-N 0.000 description 1
- QTXROIYHFXGFOW-AATRIKPKSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2C/C=C/CN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2C/C=C/CN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl QTXROIYHFXGFOW-AATRIKPKSA-N 0.000 description 1
- DXTKWQFMIQLLCM-IHWYPQMZSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2C/C=C\CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2C/C=C\CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl DXTKWQFMIQLLCM-IHWYPQMZSA-N 0.000 description 1
- QFJNLLJDFUKWGC-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CC#CCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CC#CCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl QFJNLLJDFUKWGC-UHFFFAOYSA-N 0.000 description 1
- CZWUCVILNOXSKY-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CC1=CC(N2CCN(C3=CC=C(F)C=C3)CC2)=CC=C1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CC1=CC(N2CCN(C3=CC=C(F)C=C3)CC2)=CC=C1.[H]Cl.[H]Cl CZWUCVILNOXSKY-UHFFFAOYSA-N 0.000 description 1
- RMTJTBWNCWHNAB-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCC(=O)N1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCC(=O)N1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl RMTJTBWNCWHNAB-UHFFFAOYSA-N 0.000 description 1
- QEGWSQXCPANJBW-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl QEGWSQXCPANJBW-UHFFFAOYSA-N 0.000 description 1
- JZDLOHNZRFGKSN-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl JZDLOHNZRFGKSN-UHFFFAOYSA-N 0.000 description 1
- DIWIOERUEWEFBJ-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CC=C(C2=CC=C(F)C=C2)CC1 Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CC=C(C2=CC=C(F)C=C2)CC1 DIWIOERUEWEFBJ-UHFFFAOYSA-N 0.000 description 1
- XLGJTVLQPKATNL-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=C(F)C=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=C(F)C=C(F)C=C2)CC1.[H]Cl.[H]Cl XLGJTVLQPKATNL-UHFFFAOYSA-N 0.000 description 1
- LELXHAKZPFZQRO-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(C)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(C)C=C2)CC1.[H]Cl.[H]Cl LELXHAKZPFZQRO-UHFFFAOYSA-N 0.000 description 1
- FDLZIGLVMSJOTM-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=CC=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=CC=C2)CC1.[H]Cl.[H]Cl FDLZIGLVMSJOTM-UHFFFAOYSA-N 0.000 description 1
- UZOFLFVNXWNTRG-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=NC=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=NC=C2)CC1.[H]Cl.[H]Cl UZOFLFVNXWNTRG-UHFFFAOYSA-N 0.000 description 1
- GLURKXXEOVDBIQ-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1.O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1.O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1.O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1.O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 GLURKXXEOVDBIQ-UHFFFAOYSA-N 0.000 description 1
- FEJFPWYHHOMYQQ-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(CC2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(CC2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl FEJFPWYHHOMYQQ-UHFFFAOYSA-N 0.000 description 1
- JAOYNQPGWOLFTF-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl JAOYNQPGWOLFTF-UHFFFAOYSA-N 0.000 description 1
- PSXCNMIHWYMVTJ-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2CCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl PSXCNMIHWYMVTJ-UHFFFAOYSA-N 0.000 description 1
- TUEWJTHZSPNKDE-RTBURBONSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2C[C@H]1C[C@@H]1CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2C[C@H]1C[C@@H]1CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl TUEWJTHZSPNKDE-RTBURBONSA-N 0.000 description 1
- TUEWJTHZSPNKDE-RBUKOAKNSA-N CC(=O)C1=CC=C2C(=C1)OC(=O)N2C[C@H]1C[C@H]1CN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound CC(=O)C1=CC=C2C(=C1)OC(=O)N2C[C@H]1C[C@H]1CN1CCN(C2=CC=C(F)C=C2)CC1 TUEWJTHZSPNKDE-RBUKOAKNSA-N 0.000 description 1
- NIKCPKNTCKAENL-UHFFFAOYSA-N CC(=O)C1=CC=C2OC(=O)N(CCCCN3CCN(C4=CC=C(F)C=C4)CC3)C2=C1 Chemical compound CC(=O)C1=CC=C2OC(=O)N(CCCCN3CCN(C4=CC=C(F)C=C4)CC3)C2=C1 NIKCPKNTCKAENL-UHFFFAOYSA-N 0.000 description 1
- GAJFHRHATMLERE-UHFFFAOYSA-N CC(=O)C1=CC=C2OC(=O)N(CCCCN3CCN(C4CCCCC4)CC3)C2=C1 Chemical compound CC(=O)C1=CC=C2OC(=O)N(CCCCN3CCN(C4CCCCC4)CC3)C2=C1 GAJFHRHATMLERE-UHFFFAOYSA-N 0.000 description 1
- KCHLRVRRSNUJHG-UHFFFAOYSA-N CC(=O)C1=CC=CC2=C1N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 Chemical compound CC(=O)C1=CC=CC2=C1N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 KCHLRVRRSNUJHG-UHFFFAOYSA-N 0.000 description 1
- GKLZWWHTWOFOFN-UHFFFAOYSA-N CC(=O)C1=CC=CC2=C1N(CCCCN1CCN(C3CCCCC3)CC1)C(=O)O2 Chemical compound CC(=O)C1=CC=CC2=C1N(CCCCN1CCN(C3CCCCC3)CC1)C(=O)O2 GKLZWWHTWOFOFN-UHFFFAOYSA-N 0.000 description 1
- ZUBWWAYWXHIZJS-UHFFFAOYSA-N CC(=O)C1=CC=CC2=C1OC(=O)N2CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound CC(=O)C1=CC=CC2=C1OC(=O)N2CCCCN1CCN(C2=CC=C(F)C=C2)CC1 ZUBWWAYWXHIZJS-UHFFFAOYSA-N 0.000 description 1
- FKQMTAFNNQNWOG-UHFFFAOYSA-N CC(=O)C1=CC=CC2=C1OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 Chemical compound CC(=O)C1=CC=CC2=C1OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 FKQMTAFNNQNWOG-UHFFFAOYSA-N 0.000 description 1
- BCTXRMGNXBXPPE-UHFFFAOYSA-N CC(=O)NC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 Chemical compound CC(=O)NC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 BCTXRMGNXBXPPE-UHFFFAOYSA-N 0.000 description 1
- MFDQEQRESDPEGM-UHFFFAOYSA-N CC(C)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCC(C2=CC=C(F)C=C2)CC1 Chemical compound CC(C)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCC(C2=CC=C(F)C=C2)CC1 MFDQEQRESDPEGM-UHFFFAOYSA-N 0.000 description 1
- OSYZJRKQCDVXJT-UHFFFAOYSA-N CC(C)C1CC(C)(C)NC(C)(C)C1.CC(C)C1CCCN1C.CC(C)C1CCN(C)CC1.CC(C)C1CCNCC1.CC(C)C1CN2CCC1CC2.CC1CC(O)CN1.CCCCN1CCC(C(C)C)CC1.CCN1CCC(C(C)C)CC1.CCN1CCCC(C(C)C)C1 Chemical compound CC(C)C1CC(C)(C)NC(C)(C)C1.CC(C)C1CCCN1C.CC(C)C1CCN(C)CC1.CC(C)C1CCNCC1.CC(C)C1CN2CCC1CC2.CC1CC(O)CN1.CCCCN1CCC(C(C)C)CC1.CCN1CCC(C(C)C)CC1.CCN1CCCC(C(C)C)C1 OSYZJRKQCDVXJT-UHFFFAOYSA-N 0.000 description 1
- FUUKSUJWLQEHGN-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)OCCCC2=CC3=C(C=C2)N(CCN2CCCCCC2)C(=O)S3)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)OCCCC2=CC3=C(C=C2)N(CCN2CCCCCC2)C(=O)S3)C=C1 FUUKSUJWLQEHGN-UHFFFAOYSA-N 0.000 description 1
- AUCYWVMFVWLGJI-UHFFFAOYSA-N CC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(Cl)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(Cl)C=C2)CC1.[H]Cl.[H]Cl AUCYWVMFVWLGJI-UHFFFAOYSA-N 0.000 description 1
- LBYGLBIIYDURRX-UHFFFAOYSA-N CC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(N)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(N)C=C2)CC1.[H]Cl.[H]Cl LBYGLBIIYDURRX-UHFFFAOYSA-N 0.000 description 1
- QFTTVAGCWMNDSO-UHFFFAOYSA-N CCC(=O)C1=CC2=C(C=C1)OC(=O)N2CCN1CCCCCC1.[H]Cl Chemical compound CCC(=O)C1=CC2=C(C=C1)OC(=O)N2CCN1CCCCCC1.[H]Cl QFTTVAGCWMNDSO-UHFFFAOYSA-N 0.000 description 1
- WMGOGQQUYCBJLB-UHFFFAOYSA-N CCC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound CCC(=O)C1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl WMGOGQQUYCBJLB-UHFFFAOYSA-N 0.000 description 1
- HWLXQCIHHQWINI-UHFFFAOYSA-N CCC(=O)C1=CC=C2C(=C1)SC(=O)N2CCN1CCCCCC1.Cl Chemical compound CCC(=O)C1=CC=C2C(=C1)SC(=O)N2CCN1CCCCCC1.Cl HWLXQCIHHQWINI-UHFFFAOYSA-N 0.000 description 1
- MXIAAICULRZYEO-UHFFFAOYSA-N CCC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 Chemical compound CCC1=CC=C2C(=C1)OC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 MXIAAICULRZYEO-UHFFFAOYSA-N 0.000 description 1
- QMBKEBNPQNCTNQ-UHFFFAOYSA-N CCC1=CC=C2OC(=O)N(CCCCN3CCN(C4CCCCC4)CC3)C2=C1 Chemical compound CCC1=CC=C2OC(=O)N(CCCCN3CCN(C4CCCCC4)CC3)C2=C1 QMBKEBNPQNCTNQ-UHFFFAOYSA-N 0.000 description 1
- TWFWKLVRNDTBQS-UHFFFAOYSA-N CCCC1=CC2=C(C(Br)=C1)N(CCN1CCCCCC1)C(=O)S2 Chemical compound CCCC1=CC2=C(C(Br)=C1)N(CCN1CCCCCC1)C(=O)S2 TWFWKLVRNDTBQS-UHFFFAOYSA-N 0.000 description 1
- GMJFRVHXCHVFBO-UHFFFAOYSA-N CCCC1=CC2=C(C=C1)OC(=O)N2CCN1CCCCCC1.[H]Cl Chemical compound CCCC1=CC2=C(C=C1)OC(=O)N2CCN1CCCCCC1.[H]Cl GMJFRVHXCHVFBO-UHFFFAOYSA-N 0.000 description 1
- OBFIIMSBGOVSLO-UHFFFAOYSA-N CCCCCCC(=O)C1=CC=C2C(=C1)SC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 Chemical compound CCCCCCC(=O)C1=CC=C2C(=C1)SC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 OBFIIMSBGOVSLO-UHFFFAOYSA-N 0.000 description 1
- AFKAGWACOLTCDM-UHFFFAOYSA-N CCCCCCCC1=CC=C2C(=C1)SC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 Chemical compound CCCCCCCC1=CC=C2C(=C1)SC(=O)N2CCCCN1CCN(C2CCCCC2)CC1 AFKAGWACOLTCDM-UHFFFAOYSA-N 0.000 description 1
- ISJFLJLQDSWQTB-UHFFFAOYSA-N CN1C(=O)N(CCCCN2CCN(C3=C([N+](=O)[O-])C=C(F)C=C3)CC2)C2=C1C=CC=C2 Chemical compound CN1C(=O)N(CCCCN2CCN(C3=C([N+](=O)[O-])C=C(F)C=C3)CC2)C2=C1C=CC=C2 ISJFLJLQDSWQTB-UHFFFAOYSA-N 0.000 description 1
- ZHOKGRSOBIVAGC-UHFFFAOYSA-N CN1C(=O)N(CCCCN2CCN(C3=CC=C(F)C=C3)CC2)C2=CC=CC=C21 Chemical compound CN1C(=O)N(CCCCN2CCN(C3=CC=C(F)C=C3)CC2)C2=CC=CC=C21 ZHOKGRSOBIVAGC-UHFFFAOYSA-N 0.000 description 1
- WSCMDSDVNPOTBT-UHFFFAOYSA-N CN1C(=O)N(CCCCN2CCN(C3CCCCC3)CC2)C2=CC=CC=C21 Chemical compound CN1C(=O)N(CCCCN2CCN(C3CCCCC3)CC2)C2=CC=CC=C21 WSCMDSDVNPOTBT-UHFFFAOYSA-N 0.000 description 1
- NOKYFQVRRSCSOB-UHFFFAOYSA-N CN1CC2CCC(C1)C21OCC2=C1C=CC=C2.CN1CCC2(CC1)OCC1=C2C=CC=C1.CN1CCC2=C(C=CC=C2)C1.CN1CCCCCC1.CN1CCN(C2CCCCC2)CC1.COC1=CC2=C(C=C1OC)CN(C)CC2.COC1=CC=C(N2CCN(C)CC2)C=C1 Chemical compound CN1CC2CCC(C1)C21OCC2=C1C=CC=C2.CN1CCC2(CC1)OCC1=C2C=CC=C1.CN1CCC2=C(C=CC=C2)C1.CN1CCCCCC1.CN1CCN(C2CCCCC2)CC1.COC1=CC2=C(C=C1OC)CN(C)CC2.COC1=CC=C(N2CCN(C)CC2)C=C1 NOKYFQVRRSCSOB-UHFFFAOYSA-N 0.000 description 1
- DXHHQSNRWKORQC-UHFFFAOYSA-N CN1CCN(CCCCN2C(=O)OC3=CC=CC=C32)CC1 Chemical compound CN1CCN(CCCCN2C(=O)OC3=CC=CC=C32)CC1 DXHHQSNRWKORQC-UHFFFAOYSA-N 0.000 description 1
- DGOOFSQXVLVUDR-UHFFFAOYSA-N COC1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 Chemical compound COC1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 DGOOFSQXVLVUDR-UHFFFAOYSA-N 0.000 description 1
- AEDVKCYNTTVWSP-UHFFFAOYSA-N COC1=CC2=C(C=C1)N(CCCCN1CCN(C3CCCCC3)CC1)C(=O)O2 Chemical compound COC1=CC2=C(C=C1)N(CCCCN1CCN(C3CCCCC3)CC1)C(=O)O2 AEDVKCYNTTVWSP-UHFFFAOYSA-N 0.000 description 1
- VWUTUXPKWGXHEC-UHFFFAOYSA-N COC1=CC2=C(C=C1)N(CCN1CCCCCC1)C(=O)O2 Chemical compound COC1=CC2=C(C=C1)N(CCN1CCCCCC1)C(=O)O2 VWUTUXPKWGXHEC-UHFFFAOYSA-N 0.000 description 1
- FKMMUKDTVNOKQD-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)N(C)C3=CC=CC=C31)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)N(C)C3=CC=CC=C31)CC2 FKMMUKDTVNOKQD-UHFFFAOYSA-N 0.000 description 1
- DIYXMFKPHLCFOA-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)N(C3=CC=C(F)C=C3)C3=CC=CC=C31)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)N(C3=CC=C(F)C=C3)C3=CC=CC=C31)CC2 DIYXMFKPHLCFOA-UHFFFAOYSA-N 0.000 description 1
- AOOIZQSQSQJVAE-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=C1C=CC(N(=O)[O-])=C3)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=C1C=CC(N(=O)[O-])=C3)CC2 AOOIZQSQSQJVAE-UHFFFAOYSA-N 0.000 description 1
- VRGQMAYHVPBPRJ-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=C1C=CC(OCC1=CC=CC=C1)=C3)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=C1C=CC(OCC1=CC=CC=C1)=C3)CC2 VRGQMAYHVPBPRJ-UHFFFAOYSA-N 0.000 description 1
- MHHZSBWTGAAIGY-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=CC(C(C)=O)=CC=C31)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=CC(C(C)=O)=CC=C31)CC2 MHHZSBWTGAAIGY-UHFFFAOYSA-N 0.000 description 1
- AAUSJRPYEJRBNA-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=CC=C(C(C)=O)C=C31)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=CC=C(C(C)=O)C=C31)CC2 AAUSJRPYEJRBNA-UHFFFAOYSA-N 0.000 description 1
- RJOLCJAZFJGNAH-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=CC=CC=C31)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C(=O)OC3=CC=CC=C31)CC2 RJOLCJAZFJGNAH-UHFFFAOYSA-N 0.000 description 1
- XGOHTBBPROHTRG-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C(=S)SC3=CC=CC=C31)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C(=S)SC3=CC=CC=C31)CC2 XGOHTBBPROHTRG-UHFFFAOYSA-N 0.000 description 1
- SAUWBVJOXSKPQX-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCCCN1C=C(C3=CC=C(F)C=C3)C3=CC=CC=C31)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCCCN1C=C(C3=CC=C(F)C=C3)C3=CC=CC=C31)CC2 SAUWBVJOXSKPQX-UHFFFAOYSA-N 0.000 description 1
- PYFMSZVGSYBGCZ-UHFFFAOYSA-N COC1=CC=C(N2CCN(CCCCN3C(=O)OC4=C3C=CC(C(C)=O)=C4)CC2)C=C1 Chemical compound COC1=CC=C(N2CCN(CCCCN3C(=O)OC4=C3C=CC(C(C)=O)=C4)CC2)C=C1 PYFMSZVGSYBGCZ-UHFFFAOYSA-N 0.000 description 1
- PLSLEDUGHYBGPW-UHFFFAOYSA-N COC1=CC=C(N2CCN(CCCCN3C(=O)OC4=C3C=CC=C4)CC2)C=C1 Chemical compound COC1=CC=C(N2CCN(CCCCN3C(=O)OC4=C3C=CC=C4)CC2)C=C1 PLSLEDUGHYBGPW-UHFFFAOYSA-N 0.000 description 1
- WYUYFXYIJLJMSN-UHFFFAOYSA-N COC1=CC=CC(N2CCN(CCCCN3C(=O)OC4=C3C=CC=C4)CC2)=C1 Chemical compound COC1=CC=CC(N2CCN(CCCCN3C(=O)OC4=C3C=CC=C4)CC2)=C1 WYUYFXYIJLJMSN-UHFFFAOYSA-N 0.000 description 1
- MVHUACWVEDRYEH-UHFFFAOYSA-N COCCCC1=CC2=C(C=C1)N(CCN1CCCCCC1)C(=O)S2 Chemical compound COCCCC1=CC2=C(C=C1)N(CCN1CCCCCC1)C(=O)S2 MVHUACWVEDRYEH-UHFFFAOYSA-N 0.000 description 1
- REXCDIREFJIAPZ-UHFFFAOYSA-N CS(=O)(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 Chemical compound CS(=O)(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 REXCDIREFJIAPZ-UHFFFAOYSA-N 0.000 description 1
- NWWVQLXFFWHTEV-UHFFFAOYSA-N CS(=O)(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3CCCCC3)CC1)C(=O)O2 Chemical compound CS(=O)(=O)C1=CC2=C(C=C1)N(CCCCN1CCN(C3CCCCC3)CC1)C(=O)O2 NWWVQLXFFWHTEV-UHFFFAOYSA-N 0.000 description 1
- LDPKMABDAPRXMH-UHFFFAOYSA-N FC1=CC=C(C2=CN(CCCCN3CCC4(CC3)OCC3=C4C=CC=C3)C3=CC=CC=C23)C=C1 Chemical compound FC1=CC=C(C2=CN(CCCCN3CCC4(CC3)OCC3=C4C=CC=C3)C3=CC=CC=C23)C=C1 LDPKMABDAPRXMH-UHFFFAOYSA-N 0.000 description 1
- CMLNSXADDBXCGP-UHFFFAOYSA-N FC1=CC=C(C2=CN(CCCCN3CCN(C4=CC=C(F)C=C4)CC3)C3=CC=CC=C23)C=C1 Chemical compound FC1=CC=C(C2=CN(CCCCN3CCN(C4=CC=C(F)C=C4)CC3)C3=CC=CC=C23)C=C1 CMLNSXADDBXCGP-UHFFFAOYSA-N 0.000 description 1
- KCRWYMDZCWQGNF-UHFFFAOYSA-N FC1=CC=C(C2=CN(CCCCN3CCN(C4CCCCC4)CC3)C3=CC=CC=C23)C=C1 Chemical compound FC1=CC=C(C2=CN(CCCCN3CCN(C4CCCCC4)CC3)C3=CC=CC=C23)C=C1 KCRWYMDZCWQGNF-UHFFFAOYSA-N 0.000 description 1
- OGDZYJBIYQQXEO-UHFFFAOYSA-N FC1=CC=C(N2CCN(CCCCN3C(=S)SC4=CC=CC=C43)CC2)C=C1 Chemical compound FC1=CC=C(N2CCN(CCCCN3C(=S)SC4=CC=CC=C43)CC2)C=C1 OGDZYJBIYQQXEO-UHFFFAOYSA-N 0.000 description 1
- KRXYVKJBVSRNHI-UHFFFAOYSA-N FC1=CC=C(N2CCN(CCCCN3C=CC4=CC=CC=C43)CC2)C=C1 Chemical compound FC1=CC=C(N2CCN(CCCCN3C=CC4=CC=CC=C43)CC2)C=C1 KRXYVKJBVSRNHI-UHFFFAOYSA-N 0.000 description 1
- NTEIKGNKDLPTSJ-UHFFFAOYSA-N NC1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 Chemical compound NC1=CC2=C(C=C1)N(CCCCN1CCN(C3=CC=C(F)C=C3)CC1)C(=O)O2 NTEIKGNKDLPTSJ-UHFFFAOYSA-N 0.000 description 1
- SNUDTLFHTMHYMB-UHFFFAOYSA-N O=C(C1=CC=CC=C1)C1=CC2=C(C=C1)N(CCN1CCCCCC1)C(=O)S2.[H]Cl Chemical compound O=C(C1=CC=CC=C1)C1=CC2=C(C=C1)N(CCN1CCCCCC1)C(=O)S2.[H]Cl SNUDTLFHTMHYMB-UHFFFAOYSA-N 0.000 description 1
- VGSSDDUBUQFLSP-UHFFFAOYSA-N O=C(OCCCC1=CC=C2C(=C1)SC(=O)N2CCN1CCCCCC1)C1=CC=CC=C1 Chemical compound O=C(OCCCC1=CC=C2C(=C1)SC(=O)N2CCN1CCCCCC1)C1=CC=CC=C1 VGSSDDUBUQFLSP-UHFFFAOYSA-N 0.000 description 1
- FPZWWWRFHVQZLY-UHFFFAOYSA-N O=C(c1ccccc1)c(cc1O2)ccc1N(CCCCN(CC1)CCN1c(cc1)ccc1F)C2=O Chemical compound O=C(c1ccccc1)c(cc1O2)ccc1N(CCCCN(CC1)CCN1c(cc1)ccc1F)C2=O FPZWWWRFHVQZLY-UHFFFAOYSA-N 0.000 description 1
- XSCWNDBNMGIQFC-UHFFFAOYSA-N O=C1CC2=C(C=CC=C2)O1.O=C1CC2=C(C=CC=C2)S1 Chemical compound O=C1CC2=C(C=CC=C2)O1.O=C1CC2=C(C=CC=C2)S1 XSCWNDBNMGIQFC-UHFFFAOYSA-N 0.000 description 1
- QHZRNNCTVWAOND-UHFFFAOYSA-N O=C1CCN(CCCCN2C(=O)OC3=CC=CC=C32)CC1 Chemical compound O=C1CCN(CCCCN2C(=O)OC3=CC=CC=C32)CC1 QHZRNNCTVWAOND-UHFFFAOYSA-N 0.000 description 1
- SCQNOLDXMNRMIV-UHFFFAOYSA-N O=C1N(CCCCN2CCN(C3=CC=C(F)C=C3)CC2)C2=CC=CC=C2N1C1=CC=C(F)C=C1 Chemical compound O=C1N(CCCCN2CCN(C3=CC=C(F)C=C3)CC2)C2=CC=CC=C2N1C1=CC=C(F)C=C1 SCQNOLDXMNRMIV-UHFFFAOYSA-N 0.000 description 1
- PPSCVSOKTJZTIE-UHFFFAOYSA-N O=C1N(CCCCN2CCN(C3CCCCC3)CC2)C2=CC=CC=C2N1C1=CC=C(F)C=C1 Chemical compound O=C1N(CCCCN2CCN(C3CCCCC3)CC2)C2=CC=CC=C2N1C1=CC=C(F)C=C1 PPSCVSOKTJZTIE-UHFFFAOYSA-N 0.000 description 1
- LRKFNBHZVQJDLH-UHFFFAOYSA-N O=C1OC2=C(C=C(Br)C=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound O=C1OC2=C(C=C(Br)C=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 LRKFNBHZVQJDLH-UHFFFAOYSA-N 0.000 description 1
- KPGLSOIKOIJTIF-UHFFFAOYSA-N O=C1OC2=C(C=C(C3=CC=C(F)C=C3)C=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound O=C1OC2=C(C=C(C3=CC=C(F)C=C3)C=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 KPGLSOIKOIJTIF-UHFFFAOYSA-N 0.000 description 1
- GMDKRSGIJNEPIP-UHFFFAOYSA-N O=C1OC2=C(C=CC(N=C=S)=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound O=C1OC2=C(C=CC(N=C=S)=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 GMDKRSGIJNEPIP-UHFFFAOYSA-N 0.000 description 1
- LZMRTUOEDJYPGA-UHFFFAOYSA-N O=C1OC2=C(C=CC(OCC3=CC=CC=C3)=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound O=C1OC2=C(C=CC(OCC3=CC=CC=C3)=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 LZMRTUOEDJYPGA-UHFFFAOYSA-N 0.000 description 1
- XBOXWVCJACOUDL-UHFFFAOYSA-N O=C1OC2=C(C=CC(OCC3=CC=CC=C3)=C2)N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=C(C=CC(OCC3=CC=CC=C3)=C2)N1CCCCN1CCN(C2CCCCC2)CC1 XBOXWVCJACOUDL-UHFFFAOYSA-N 0.000 description 1
- KPFYYRHZCXBLBZ-UHFFFAOYSA-N O=C1OC2=C(C=CC(S(=O)(=O)N3CCCC3)=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound O=C1OC2=C(C=CC(S(=O)(=O)N3CCCC3)=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 KPFYYRHZCXBLBZ-UHFFFAOYSA-N 0.000 description 1
- PWQWXHWFWIKTJQ-UHFFFAOYSA-N O=C1OC2=C(C=CC([N+](=O)[O-])=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound O=C1OC2=C(C=CC([N+](=O)[O-])=C2)N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 PWQWXHWFWIKTJQ-UHFFFAOYSA-N 0.000 description 1
- CHGUXOKMBZASPV-ARJAWSKDSA-N O=C1OC2=C(C=CC=C2)N1C/C=C\CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound O=C1OC2=C(C=CC=C2)N1C/C=C\CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl CHGUXOKMBZASPV-ARJAWSKDSA-N 0.000 description 1
- IKXKGNKEODNFRB-UHFFFAOYSA-N O=C1OC2=C(C=CC=C2)N1CCCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=C(C=CC=C2)N1CCCCCN1CCN(C2CCCCC2)CC1 IKXKGNKEODNFRB-UHFFFAOYSA-N 0.000 description 1
- BRFWWELHJAVRBL-UHFFFAOYSA-N O=C1OC2=C(C=CC=C2)N1CCCCN1CC=C(C2=CC=C(F)C=C2)CC1 Chemical compound O=C1OC2=C(C=CC=C2)N1CCCCN1CC=C(C2=CC=C(F)C=C2)CC1 BRFWWELHJAVRBL-UHFFFAOYSA-N 0.000 description 1
- IJUATJKBMRWAFC-UHFFFAOYSA-N O=C1OC2=C(C=CC=C2)N1CCCCN1CCC2=C(C=CC=C2)C1 Chemical compound O=C1OC2=C(C=CC=C2)N1CCCCN1CCC2=C(C=CC=C2)C1 IJUATJKBMRWAFC-UHFFFAOYSA-N 0.000 description 1
- LFNRULZBGKMEAZ-UHFFFAOYSA-N O=C1OC2=C(C=CC=C2)N1CCCCN1CCN(C2=C(Cl)C(Cl)=CC=C2)CC1 Chemical compound O=C1OC2=C(C=CC=C2)N1CCCCN1CCN(C2=C(Cl)C(Cl)=CC=C2)CC1 LFNRULZBGKMEAZ-UHFFFAOYSA-N 0.000 description 1
- WVLWRGOGIBEQPD-UHFFFAOYSA-N O=C1OC2=C(C=CC=C2)N1CCCCN1CCN(C2=C(F)C=CC=C2)CC1 Chemical compound O=C1OC2=C(C=CC=C2)N1CCCCN1CCN(C2=C(F)C=CC=C2)CC1 WVLWRGOGIBEQPD-UHFFFAOYSA-N 0.000 description 1
- UPMNIUMPNZPAPK-UHFFFAOYSA-N O=C1OC2=C(C=CC=C2)N1CCCCN1CCN(C2=CC(F)=CC=C2)CC1 Chemical compound O=C1OC2=C(C=CC=C2)N1CCCCN1CCN(C2=CC(F)=CC=C2)CC1 UPMNIUMPNZPAPK-UHFFFAOYSA-N 0.000 description 1
- CKIRCWNMBOKGBF-UHFFFAOYSA-N O=C1OC2=C(C=CC=C2)N1CCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=C(C=CC=C2)N1CCN1CCN(C2CCCCC2)CC1 CKIRCWNMBOKGBF-UHFFFAOYSA-N 0.000 description 1
- CMXSXFICBACTNY-UHFFFAOYSA-N O=C1OC2=CC(Br)=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound O=C1OC2=CC(Br)=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl CMXSXFICBACTNY-UHFFFAOYSA-N 0.000 description 1
- BJAXWYVPFRXNEM-UHFFFAOYSA-N O=C1OC2=CC(Br)=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=CC(Br)=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 BJAXWYVPFRXNEM-UHFFFAOYSA-N 0.000 description 1
- GFDGWFVQYILWLP-UHFFFAOYSA-N O=C1OC2=CC(C3=CC=C(F)C=C3)=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=CC(C3=CC=C(F)C=C3)=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 GFDGWFVQYILWLP-UHFFFAOYSA-N 0.000 description 1
- IJZLASYIUNWQNL-UHFFFAOYSA-N O=C1OC2=CC(C3=CC=CC=C3)=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound O=C1OC2=CC(C3=CC=CC=C3)=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1 IJZLASYIUNWQNL-UHFFFAOYSA-N 0.000 description 1
- MEUSLJZCKMAUMM-UHFFFAOYSA-N O=C1OC2=CC([N+](=O)[O-])=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=CC([N+](=O)[O-])=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 MEUSLJZCKMAUMM-UHFFFAOYSA-N 0.000 description 1
- BFHPWXJYFHFFCS-UHFFFAOYSA-N O=C1OC2=CC=C(Br)C=C2N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=CC=C(Br)C=C2N1CCCCN1CCN(C2CCCCC2)CC1 BFHPWXJYFHFFCS-UHFFFAOYSA-N 0.000 description 1
- IWDYXCFZRFIDMV-UHFFFAOYSA-N O=C1OC2=CC=C(C3=CC=C(F)C=C3)C=C2N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=CC=C(C3=CC=C(F)C=C3)C=C2N1CCCCN1CCN(C2CCCCC2)CC1 IWDYXCFZRFIDMV-UHFFFAOYSA-N 0.000 description 1
- CHGUXOKMBZASPV-ONEGZZNKSA-N O=C1OC2=CC=CC=C2N1C/C=C/CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound O=C1OC2=CC=CC=C2N1C/C=C/CN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl CHGUXOKMBZASPV-ONEGZZNKSA-N 0.000 description 1
- BHEFIIJECZFXNQ-VOTSOKGWSA-N O=C1OC2=CC=CC=C2N1C/C=C/CN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl Chemical compound O=C1OC2=CC=CC=C2N1C/C=C/CN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl BHEFIIJECZFXNQ-VOTSOKGWSA-N 0.000 description 1
- FQUAIYXSOSIJDF-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCC1CCCCC1.[H]Cl Chemical compound O=C1OC2=CC=CC=C2N1CCCCC1CCCCC1.[H]Cl FQUAIYXSOSIJDF-UHFFFAOYSA-N 0.000 description 1
- WPZCHALBHCESQX-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCCCN1CCN(C2CCCCC2)CC1 WPZCHALBHCESQX-UHFFFAOYSA-N 0.000 description 1
- BYEKAOHFTIAERU-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCCCN1CCN(CC2=CC=CC=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCCCN1CCN(CC2=CC=CC=C2)CC1 BYEKAOHFTIAERU-UHFFFAOYSA-N 0.000 description 1
- PBVJQSODSXQLEY-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CC=C(C2=CC=C(Cl)C=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CC=C(C2=CC=C(Cl)C=C2)CC1 PBVJQSODSXQLEY-UHFFFAOYSA-N 0.000 description 1
- YTYIYWWXYTYCHB-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCC(C2=CC=CC=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCC(C2=CC=CC=C2)CC1 YTYIYWWXYTYCHB-UHFFFAOYSA-N 0.000 description 1
- NKKHRTPRYPIIOL-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCC2(CC1)OCC1=C2C=CC=C1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCC2(CC1)OCC1=C2C=CC=C1 NKKHRTPRYPIIOL-UHFFFAOYSA-N 0.000 description 1
- FLCVNIBSPSJCMV-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C([N+](=O)[O-])C=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C([N+](=O)[O-])C=C2)CC1 FLCVNIBSPSJCMV-UHFFFAOYSA-N 0.000 description 1
- ILKJKAKLGLEFPD-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=NC=CC=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2=NC=CC=C2)CC1 ILKJKAKLGLEFPD-UHFFFAOYSA-N 0.000 description 1
- WWPDOXILIDUTHY-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 WWPDOXILIDUTHY-UHFFFAOYSA-N 0.000 description 1
- MYJQFJPJDQDZII-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCN(CC2=CC=CC=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCN(CC2=CC=CC=C2)CC1 MYJQFJPJDQDZII-UHFFFAOYSA-N 0.000 description 1
- VYKDCSVQKRYGFX-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCN(CC2CC2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCN(CC2CC2)CC1 VYKDCSVQKRYGFX-UHFFFAOYSA-N 0.000 description 1
- MFDQZXJQNRUGNV-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCN(CC2CCCCC2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCN(CC2CCCCC2)CC1 MFDQZXJQNRUGNV-UHFFFAOYSA-N 0.000 description 1
- NTXNQXHENQWIED-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCCCN1CCN(CCC2=CC=CC=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCCCN1CCN(CCC2=CC=CC=C2)CC1 NTXNQXHENQWIED-UHFFFAOYSA-N 0.000 description 1
- FGZJPJFNCSHDFL-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCN1CC=C(C2=CC=C(Cl)C=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCN1CC=C(C2=CC=C(Cl)C=C2)CC1 FGZJPJFNCSHDFL-UHFFFAOYSA-N 0.000 description 1
- DSXGXHVTSKGARP-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCN1CCC(C2=CC=CC=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCN1CCC(C2=CC=CC=C2)CC1 DSXGXHVTSKGARP-UHFFFAOYSA-N 0.000 description 1
- XUONGGFXKKCBKN-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCN1CCN(C2=CC=C(Cl)C=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCN1CCN(C2=CC=C(Cl)C=C2)CC1 XUONGGFXKKCBKN-UHFFFAOYSA-N 0.000 description 1
- DIGYAOVNWSEWNC-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCN1CCN(C2=NC=CC=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCN1CCN(C2=NC=CC=C2)CC1 DIGYAOVNWSEWNC-UHFFFAOYSA-N 0.000 description 1
- TZNNOXAZJZLDTJ-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCN1CCN(CC2CCCCC2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCN1CCN(CC2CCCCC2)CC1 TZNNOXAZJZLDTJ-UHFFFAOYSA-N 0.000 description 1
- ZRPLYYBNVMGQJA-UHFFFAOYSA-N O=C1OC2=CC=CC=C2N1CCN1CCN(CCC2=CC=CC=C2)CC1 Chemical compound O=C1OC2=CC=CC=C2N1CCN1CCN(CCC2=CC=CC=C2)CC1 ZRPLYYBNVMGQJA-UHFFFAOYSA-N 0.000 description 1
- NWVUMZVZGLWRNH-UHFFFAOYSA-N O=C1SC2=C(C(Br)=CC(CCCF)=C2)N1CCN1CCCCCC1 Chemical compound O=C1SC2=C(C(Br)=CC(CCCF)=C2)N1CCN1CCCCCC1 NWVUMZVZGLWRNH-UHFFFAOYSA-N 0.000 description 1
- IZPZSAXEBNPWOM-UHFFFAOYSA-N O=C1SC2=C(C=CC(CC3=CC=CC=C3)=C2)N1CCN1CCCCCC1.[H]Cl Chemical compound O=C1SC2=C(C=CC(CC3=CC=CC=C3)=C2)N1CCN1CCCCCC1.[H]Cl IZPZSAXEBNPWOM-UHFFFAOYSA-N 0.000 description 1
- ABRWZQBRPDGTKL-UHFFFAOYSA-N O=C1SC2=C(C=CC(CCCBr)=C2)N1CCN1CCCCCC1 Chemical compound O=C1SC2=C(C=CC(CCCBr)=C2)N1CCN1CCCCCC1 ABRWZQBRPDGTKL-UHFFFAOYSA-N 0.000 description 1
- WAFURAOAPIYYOH-UHFFFAOYSA-N O=C1SC2=C(C=CC(CCCCl)=C2)N1CCN1CCCCCC1 Chemical compound O=C1SC2=C(C=CC(CCCCl)=C2)N1CCN1CCCCCC1 WAFURAOAPIYYOH-UHFFFAOYSA-N 0.000 description 1
- RBFYCCBQEYXNHK-UHFFFAOYSA-N O=C1SC2=C(C=CC=C2)N1CCN1CCCCCC1 Chemical compound O=C1SC2=C(C=CC=C2)N1CCN1CCCCCC1 RBFYCCBQEYXNHK-UHFFFAOYSA-N 0.000 description 1
- DHPSNZMSULXNBM-UHFFFAOYSA-N O=C1SC2=CC(CCCO)=CC=C2N1CCN1CCCCCC1 Chemical compound O=C1SC2=CC(CCCO)=CC=C2N1CCN1CCCCCC1 DHPSNZMSULXNBM-UHFFFAOYSA-N 0.000 description 1
- YQBLPRIQIPGWFI-UHFFFAOYSA-N O=C1SC2=CC=CC=C2N1CCCCCN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl Chemical compound O=C1SC2=CC=CC=C2N1CCCCCN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl YQBLPRIQIPGWFI-UHFFFAOYSA-N 0.000 description 1
- MKTMTTALPIYYMB-UHFFFAOYSA-N O=C1SC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl Chemical compound O=C1SC2=CC=CC=C2N1CCCCN1CCN(C2=CC=C(F)C=C2)CC1.[H]Cl.[H]Cl MKTMTTALPIYYMB-UHFFFAOYSA-N 0.000 description 1
- KUIPFHRLGGNMLR-UHFFFAOYSA-N O=C1SC2=CC=CC=C2N1CCCN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl Chemical compound O=C1SC2=CC=CC=C2N1CCCN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl KUIPFHRLGGNMLR-UHFFFAOYSA-N 0.000 description 1
- DIBZOKFDPDYODL-UHFFFAOYSA-N O=C1SC2=CC=CC=C2N1CCN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl Chemical compound O=C1SC2=CC=CC=C2N1CCN1CCN(C2CCCCC2)CC1.[H]Cl.[H]Cl DIBZOKFDPDYODL-UHFFFAOYSA-N 0.000 description 1
- FIQKIWMXLKEGEM-UHFFFAOYSA-N S=C1OC2=CC=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound S=C1OC2=CC=CC=C2N1CCCCN1CCN(C2CCCCC2)CC1 FIQKIWMXLKEGEM-UHFFFAOYSA-N 0.000 description 1
- FJGOTAJCEJCFEV-UHFFFAOYSA-N S=C1SC2=C(C=CC=C2)N1CCCCN1CCN(C2CCCCC2)CC1 Chemical compound S=C1SC2=C(C=CC=C2)N1CCCCN1CCN(C2CCCCC2)CC1 FJGOTAJCEJCFEV-UHFFFAOYSA-N 0.000 description 1
- SJPNCRRYCUGOKW-UHFFFAOYSA-N S=C1SC2=CC=CC=C2N1CCCCN1CCC2(CC1)OCC1=C2C=CC=C1 Chemical compound S=C1SC2=CC=CC=C2N1CCCCN1CCC2(CC1)OCC1=C2C=CC=C1 SJPNCRRYCUGOKW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- the subject invention was made with government support under a research project supported by the United States Government in NIDA Grant Numbers DA023205, DA011979, DA013978 and NCRR P20 RR021929 and the government has certain rights to this invention.
- the present invention relates to the field of compounds which are sigma receptor ligands and methods of use thereof as sigma receptor ligands.
- Sigma receptors have received much attention from the drug discovery field due to their possible involvement in schizophrenia, regulation of motor behavior, convulsions, anxiety, and the psychostimulant effects of drugs of abuse including cocaine, methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA).
- MDMA 3,4-methylenedioxymethamphetamine
- 1,2 In addition to a host of neurological and psychiatric areas of interest, sigma receptors are promising drug development targets for, ontological, immunological, cardiovascular, opthalmological, developmental, gastrointestinal and metabolic disorders as well as those affecting the endocrine system. They are structurally unique proteins that are distinct from classical G protein-coupled receptors, ionotropic receptors, or receptor tyrosine kinases. With two subtypes currently known, they modulate cell survival and excitability, and subserve many critical functions in the body. Endogenous ligands for these receptors are unknown, though current clues point to neurosteroids. 3
- the 223 amino acid ⁇ -1 protein with two transmembrane spanning regions has been purified and cloned from several animal species including mouse, rat, guinea pig, and human. 4-8
- the ⁇ -1 receptor is well studied and known because of the receptor sequence information and availability of selective ⁇ -1 ligands. But, the protein corresponding to ⁇ -2 sites has not yet been cloned.
- ⁇ -2 receptor-selective ligands are less common, with tritiated DTG (1,3-di(2-tolyl)guanidine) being accepted as a radioligand in the presence of (+)-pentazocine (to block binding to ⁇ -1 sites). Due to the lack of availability of detailed protein structural information and truly selective ⁇ -2 ligands, the pharmacological characterization of the ⁇ -2 subtype has been very limited. There is clearly a need for a selective ⁇ -2 ligand which can not only act as a probe to explore unknown biochemical mechanisms, but also be used as a radioligand in ⁇ -2 receptor binding assays.
- Cocaine use and abuse has been reported as early as the late 1500s. 9 The historical use has been associated with the chewing of leaves from the Erythroxylon coca bush, from which cocaine was isolated in 1860, 10 to eliminate fatigue in workers. Indeed, cocaine is a powerful and addictive psychostimulant. Cocaine abuse is widespread and is responsible for more serious intoxications and deaths than any other illicit drug. However, the invigorating effects of cocaine have caused it to become a major recreational drug of abuse throughout the world with an estimated 13 million people using the drug. In 2004, 34.2 million Americans aged 12 and over reported lifetime use of cocaine with approximately 5.6 million reporting annual use and an estimated 2 million reporting current use of the drug. In 2004 alone, there were an estimated 1 million new users of cocaine amounting to 2,700 per day.
- the present invention relates to compounds useful as sigma receptors of the following formula I:
- R 1 can be an optionally substituted nitrogen-containing heterocycle radical such as, for example, radicals of optionally substituted piperidines, optionally substituted piperazines, optionally substituted tetrahydropyridines, optionally substituted azepanes, tertiary amines (cyclic or acyclic), isoindoline-1,3-dione, or optionally substituted tetrahydroisoquinolones (aromatically substituted):
- R 2,3,4,5,6 can each independently be any one or combinations of the following moieties, such as, for example, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate anilino (unsubstituted or substituted), halogens (such as fluorine, chlorine, bromide and iodine), ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic
- Z can be either H, O, S, S—R or NR.
- R groups can be either H, aryls, alkyls, or cycloalkyls.
- “n” can be 1 to 5 carbons in length and stereoisomers, analogs, and pharmaceutically acceptable salts thereof as well as compositions comprising said compounds.
- the moiety bridging R 1 and N in the formula I can be an optionally substituted C 1 -C 6 alkylene, C 1 -C 6 alkenylene or C 1 -C 6 alkynylene group wherein the alkylene group can have inserted into its chain a C 3 -C 5 cycloalkyl group, aromatic, and heterocyclic group.
- FIG. 1 SN79 attenuates the convulsive effects of cocaine (***P ⁇ 0.005)
- FIG. 2 SN79 pretreatment attenuates cocaine-induced locomotor activity (*P ⁇ 0.05, **P ⁇ 0.01)
- FIG. 3 SN79 pretreatment attenuates the development of cocaine-induced sensitization (*P ⁇ 0.05, #P ⁇ 0.05)
- FIG. 4 SN79 pretreatment attenuates the expression of cocaine-induced sensitization (**P ⁇ 0.05 vs sensitized, ##P ⁇ 0.05 vs acute cocaine)
- FIG. 5 CM156 attenuates the convulsive effects of cocaine (***P ⁇ 0.005)
- FIG. 6 CM156 pretreatment attenuates cocaine-induced locomotor activity (*P ⁇ 0.05)
- FIG. 7 CM156 pretreatment attenuates the expression of cocaine-induced sensitization (*P ⁇ 0.05 vs sensitized, #P ⁇ 0.05 vs acute cocaine)
- FIG. 8 CM156 pretreatment attenuates methamphetamine-induced locomotor activity (#P ⁇ 0.05)
- FIG. 9 CM156 pretreatment attenuates methamphetamine-induced dopamine depletions (**P ⁇ 0.05, ##P ⁇ 0.05)
- the generic structure of Formula I encompasses a diverse range of heterocycles.
- the 2(3H)-benzoxazolone (BOA) and its bioisosteric surrogate 2(3H)-benzothiazolone (BTA) heterocycle is a bicyclic ring system which promotes high versatility in organic synthesis involving N-substitution (either N-alkylation or N-acylation) and aromatic ring electrophilic substitution reactions.
- the present invention relates to compounds having the general formula I
- R 1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle or a radical of an optionally substituted cyclic or acyclic tertiary amine, or isoindoline-1,3-dioneR 2,3,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanates, isocyanates, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Y can be either CH, CH 2 , O, S, OCH 2 , N—R, N—Ar, C—R, C—Ar; Z can be either H, O, S, S—R or NR.
- R groups can be either H, aryls, alkyls, or cycloalkyls; “n” can be 1 to 5 carbons in length and stereoisomers, functional analogs, and pharmaceutically acceptable salts thereof and wherein the moiety bridging R 1 and N can be optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene and where the alkylene group can include an inserted C 3 -C 5 cycloalkyl group, aromatic and heterocycle group.
- the optionally substituted N-containing heterocyclic radical can be for example optionally substituted piperidine, optionally substituted tetrahydropiperidine, optionally substituted piperazine, optionally substituted tetrahydropyridine, optionally substituted azepanes or optionally substituted tetrahydroisoquinoline in which the optional substituents are on the aromatic moiety.
- R 1 for example is optionally substituted
- lower refers to a group having between one and six carbons.
- alkyl refers to a straight or branched chain hydrocarbon having from one to ten carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, azido, isothiocyanate, isocyanate, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- alkyl may contain one or more O, S, S(O), or S(O) 2 atoms.
- alkyl as used herein include, but are not limited to, methyl, n-butyl, t-butyl, n-pentyl, isobutyl, and isopropyl, and the like.
- alkylene refers to a straight or branched chain divalent hydrocarbon radical having from one to ten carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- Such an “alkylene” group may contain one or more O, S, S(O), or S(O) 2 atoms. Examples
- alkenyl refers to a hydrocarbon radical having from two to ten carbons and at least one carbon-carbon double bond, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- Such an “alkenyl” group may contain one or more O, S, S(O), or S(O) 2 atoms.
- alkenylene refers to a straight or branched chain divalent hydrocarbon radical having from two to ten carbon atoms and one or more carbon-carbon double bonds, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- alkenylene may contain one or more O, S, S(O), or S(O) 2 atoms.
- alkenylene as used herein include, but are not limited to, ethene-1,2-diyl, propene-1,3-diyl, methylene-1,1-diyl, and the like.
- alkynyl refers to a hydrocarbon radical having from two to ten carbons and at least one carbon-carbon triple bond, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- Such an “alkynyl” group may contain one or more O, S, S(O), or S(O) 2 atom
- alkynylene refers to a straight or branched chain 5 divalent hydrocarbon radical having from two to ten carbon atoms and one or more carbon-carbon triple bonds, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- alkynylene may contain one or more O, S, S(O), or S(O) 2 atoms.
- alkynylene as used herein include, but are not limited to, ethyne-1,2-diyl, propyne-1,3-diyl, and the like.
- cycloalkyl refers to an alicyclic hydrocarbon group optionally possessing one or more degrees of unsaturation, having from three to twelve carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- Cycloalkyl includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, and the like.
- cycloalkylene refers to a non-aromatic alicyclic divalent hydrocarbon radical having from three to twelve carbon atoms and optionally possessing one or more degrees of unsaturation, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- cycloalkylene examples include, but are not limited to, cyclopropyl-1,1-diyl, cyclopropyl-1,2-diyl, cyclobutyl-1,2-diyl, cyclopentyl-1,3-diyl, cyclohexyl-1,4-diyl, cycloheptyl-1,4-diyl, or cyclooctyl-1,5-diyl, and the like.
- heterocyclic or the term “heterocyclyl” refers to a three to twelve-membered heterocyclic ring optionally possessing one or more degrees of unsaturation, containing one or more heteroatomic substitutions selected from S, SO, SO 2 , O, or N, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- Such a ring may be optionally fused to one or more of another “heterocyclic” ring(s) or cycloalkyl ring(s).
- heterocyclic include, but are not limited to, tetrahydrofuran, 1,4-dioxane, 1,3-dioxane, piperidine, pyrrolidine, morpholine, piperazine, tetrahydropyridine, hexagydroazepine and the like.
- heterocyclyl containing at least one basic nitrogen atom refers to a “heterocyclic” or “heterocyclyl” group as defined above, wherein said heterocyclyl group contains at least one nitrogen atom flanked by 20 hydrogen, alkyl, alkylene, or alkylyne groups, wherein said alkyl and/or alkylene groups are not substituted by oxo.
- heterocyclyl containing at least one basic nitrogen atom include, but are not limited to, piperazine-2-yl, pyrrolidine-2-yl, azepine-4-yl,
- heterocyclylene refers to a three to twelve-membered heterocyclic ring diradical optionally having one or more degrees of unsaturation containing one or more heteroatoms selected from S, SO, SO 2 , O, or N, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed.
- Such a ring may be optionally fused to one or more benzene rings or to one or more of another “heterocyclic” rings or cycloalkyl rings.
- heterocyclylene include, but are not limited to, tetrahydrofuran-2,5-diyl, morpholine-2,3-diyl, pyran-2,4-diyl, 1,4-dioxane-2,3-diyl, 1,3-dioxane-2,4-diyl, piperidine-2,4-diyl, piperidine-1,4-diyl, pyrrolidine-1,3-diyl, morpholine-2,4-diyl, piperazine-1,4-diyl, and the like.
- aryl refers to a benzene ring or to an optionally substituted benzene ring system fused to one or more optionally substituted benzene rings, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy optionally substituted by acyl, mercapto, azido, isothiocyanate, isocyanate, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, silyloxy optionally substituted by alkoxy, alkyl, or ary
- arylene refers to a benzene ring diradical or to a benzene ring system diradical fused to one or more optionally substituted benzene rings, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, silyl optionally
- heteroaryl refers to a five- to seven-membered aromatic ring, or to a polycyclic heterocyclic aromatic ring, containing one or more nitrogen, oxygen, or sulfur heteroatoms, where N-oxides and sulfur monoxides and sulfur dioxides are permissible heteroaromatic substitutions, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, silyloxy optionally substituted by
- one or more of the rings may contain one or more heteroatoms.
- heteroaryl used herein are furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, quinazoline, benzofuran, benzothiophene, indole, and indazole, and the like.
- heteroarylene refers to a five- to seven-membered aromatic ring diradical, or to a polycyclic heterocyclic aromatic ring diradical, containing one or more nitrogen, oxygen, or sulfur heteroatoms, where N-oxides and sulfur monoxides and sulfur dioxides are permissible heteroaromatic substitutions, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, silyl
- heteroarylene used herein are furan-2,5-diyl, thiophene-2,4-diyl, 1,3,4-oxadiazole-2,5-diyl, 1,3,4-thiadiazole-2,5-diyl, 1,3-thiazole-2,4-diyl, 1,3-thiazole-2,5-diyl, pyridine-2,4-diyl, pyridine-2,3-diyl, pyridine-2,5-diyl, pyrimidine-2,4-diyl, quinoline-2,3-diyl, and the like.
- CM121 showed a six fold preference for the ⁇ -2 subtype, suggesting that a four methylene spacer between the piperazine ring and the heterocycle may favor ⁇ -2 affinity (Table 1, Scheme 1).
- compound CM170 was found to have an 11 fold preference for the ⁇ -2 subtype, suggesting a 4-fluoropiperazine moiety may favor ⁇ -2 affinity (Scheme 1).
- CM142 having a 6-acetyl group in the 2(3H)-benzoxazolone heterocycle increased the preference for ⁇ -2 receptors by 7 fold (Scheme 1).
- SN79 (Scheme 2) showed the highest selectivity (>16,500 fold) for the ⁇ -2 subtype suggesting that a four methylene linker, a 6-acetyl group in the 2(3H)-benzoxazolone heterocycle and a 4-fluoropiperazine moiety favor ⁇ -2 affinity over the ⁇ -1 subtype.
- CM156 (Scheme 3), where the 2-oxo is replaced with a sulfur, demonstrated the highest affinity for both subtypes and was therefore examined in several non-sigma binding assays as shown in table 4. CM156 had much weaker affinity for other proteins of interest, confirming preferential affinity for sigma receptors.
- CM156 was further investigated in vivo for antagonizing effects in cocaine treated mice. Pretreatment of mice with CM156 led to a significant attenuation of cocaine-induced convulsions, locomotor activity and behavioral sensitization as seen in FIGS. 5-7 . Compound CM156 was additionally investigated for its ability to attenuate methamphetamine-induced locomotor stimulation and neurotoxicity in mice. As seen in FIGS. 8 and 9 , CM156 attenuated the locomotor stimulant effects of methamphetamine as well as the neurotoxic effects resulting from methamphetamine exposures. Together, these data demonstrate that CM156 with high affnitity for both a subtypes can mitigate a variety of drug-induced effects, both from cocaine and methamphetamine, in vivo.
- the compounds of the present invention are for use as novel radioligands and agents for treatment of drugs of abuse including cocaine- and methamphetamine-induced abuse and toxicities.
- the radioligands to label the sites of interest and compounds to define non-specific binding were as follows: dopamine transporters (0.5 nM [ 3 H]WIN35,428, 50 ⁇ M cocaine), serotonin transporters (0.2 nM [ 3 H]paroxetine, 1.5 ⁇ M imipramine), norepinephrine transporters (0.5 nM [ 3 H]nisoxetine, 4 ⁇ M desipramine), opioid receptors (2 nM [ 3 H]bremazocine, 10 ⁇ M levollorphan), NMDA receptors (5 nM [ 3 H]TCP, 10 ⁇ M cyclazocine), dopamine D 2 receptors (5 nM [ 3 H](+)-sulpiride, 1 ⁇ M haloperidol), and 5-HT 2 receptors (2 nM [ 3 H]ketanserin, 1 ⁇ M mianserin). The results were reported as K i in nM. If after three independent replications of the assay, the 10,000 nM concentration of the
- mice Male, Swiss Webster mice were pretreated (i.p.) with saline or compound (0.1-10 mg/kg), then challenged 15 min later with a convulsive dose of cocaine (70 mg/kg, i.p.). Mice were observed for the next 30 min for convulsions, which were defined as a loss of righting reflexes for at least 5 sec combined with the presence of clonic limb movements or popcorn jumping. Fisher's exact test was used to determine whether the effect produced by pretreatment with a particular drug dose differed significantly from pretreatment with the saline control.
- mice Male, Swiss Webster mice were acclimated to the treatment room and then to the chambers of the automated activity monitoring system (San Diego Instruments, San Diego, Calif.). They were injected (i.p.) with saline or compound (0.1-20 mg/kg), then challenged 15 min later with cocaine (20 mg/kg, i.p.) or saline (i.p). The total locomotor activity (ambulatory, fine and rearing movements) of the mice was recorded for the next 30 min as the number of disruptions made by them in the 16 ⁇ 16 photobeam grid of their testing chamber.
- automated activity monitoring system San Diego Instruments, San Diego, Calif.
- mice Male, Swiss Webster mice were acclimated as detailed above. For five consecutive days (Days 1-5), the mice were pretreated (i.p.) with saline or compound (0.1-20 mg/kg), then challenged 15 min later with cocaine (10 mg/kg, i.p.) or saline (i.p.). The total locomotor activity (ambulatory, fine and rearing movements) of the mice was recorded for the next 30 min as the number of disruptions made by them in the 16 ⁇ 16 photobeam grids of their testing chamber on each of the five days. A 10 day drug-free period followed. On Day 15, all of the mice were pre-administered (i.p.) saline followed by cocaine (10 mg/kg, i.p.), and locomotor activity quantified for the next 30 min.
- cocaine mg/kg, i.p.
- mice Male, Swiss Webster mice were acclimated as detailed above. For five consecutive days (Days 1-5), the mice were pretreated (i.p) with saline, then challenged 15 min later with cocaine (10 mg/kg, i.p.). The total locomotor activity (ambulatory, fine and rearing movements) of the mice was recorded for the next 30 min. A 10 day drug free period followed and on Day 15, the mice were administered saline (i.p.) or compound (0.1-20 mg/kg), followed 15 min later with cocaine (10 mg/kg, i.p.). Locomotor activity was then recorded for the next 30 min.
- mice Male, Swiss Webster mice were acclimated as detailed above. They were injected (i.p.) with saline or compound (0.1-20 mg/kg), then challenged 15 min later with methamphetamine (1 mg/kg, i.p.) or saline (i.p). The total locomotor activity (ambulatory, fine and rearing movements) of the mice was recorded for the next 30 min as the number of disruptions made by them in the 16 ⁇ 16 photobeam grids surrounding their testing chambers.
- mice Male, Swiss Webster mice were injected (i.p.) with saline or compound (0-20 mg/kg), followed 15 min later with either saline ( ⁇ METH) or methamphetamine (5 mg/kg) at 2 hr intervals, a total of four times. Striatal dopamine levels were measured one week later.
- the present invention comprises a method of treating a subject for alleviation of affects in the subject resulting from drug intake or drug abuse by the subject comprising administering to the subject a therapeutically effective amount of at least one compound according to the invention.
- the drug abuse or drug intake can result from methamphetamine intake or methamphetamine abuse by the subject or from cocaine abuse or cocaine intake by the subject.
- the present invention further comprises a method of treating a subject having a need for therapy involving sigma receptors comprising administering to the subject an effective amount of at least one compound of the present invention and additionally comprises treating a subject to prevent neurotoxic effects resulting from drug abuse or drug intake by the subject comprising administering to the subject a therapeutically effective amount of at least one compound according to the invention.
- the invention further comprises radioligand compositions comprising at least one compound according to the invention wherein at least one compound contains a radioactive element.
- compositions according to the invention are those which are suitable for enteral, such as oral, administration and for parenteral, such as subcutaneous, administration to warm-blooded animals, especially humans, and which contain the pharmacologically active substance on its own or together with a pharmaceutically acceptable carrier.
- enteral such as oral, administration and for parenteral, such as subcutaneous, administration to warm-blooded animals, especially humans, and which contain the pharmacologically active substance on its own or together with a pharmaceutically acceptable carrier.
- the dosage of the active substance depends on the species of warm-blooded animal and on the age and individual condition, the illness to be treated and also on the mode of administration. Such dosage can be readily determined by those practicing in the relevant art area.
- novel pharmaceutical preparations contain from approximately 10% to approximately 95%, and preferably from approximately 20% to approximately 90%, of the active substance.
- Pharmaceutical compositions according to the invention can, for example, be in unit dose form, such as dragees, tablets, capsules, suppositories or ampoules.
- compositions of the present invention are manufactured in a manner known per se, for example, by means of conventional mixing, granulating, confectioning, dissolving or lyophilizing processes.
- Pharmaceutical compositions for oral use can be obtained by combining the active substance with one or more solid carriers, if desired, granulating a resulting mixture and processing the mixture or granulate, if desired or necessary after the addition of suitable adjuncts, to form tablets or dragee cores. In so doing, they can also be incorporated into plastics carriers which release the active substances or allow them to diffuse in controlled amounts.
- Suitable carriers are especially fillers such as sugars, for example, lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, also binders such as starches, for example, corn, wheat, rice or potato starch, gelatine, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators such as the above-mentioned starches, also carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, alginic acid or a salt thereof such as sodium alginate.
- fillers such as sugars, for example, lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, also
- Adjuncts are especially flow-regulating and lubricating agents, for example, silica, talc, stearic acid or salts thereof such as magnesium or calcium stearate, and/or polyethylene glycol.
- Dragee cores are provided with suitable coatings that are, if desired, resistant to gastric juice, there being used, inter alia, concentrated sugar solutions which optionally contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions in suitable organic solvents or solvent mixtures or, for the manufacture of coatings that are resistant to gastric juice, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Coloring substances or pigments can be added to the tablets or dragee coatings, for example for the purpose of identification or for indicating different doses of active substance.
- compositions are dry-filled capsules made of gelatin and also soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the dry-filled capsules may contain the active ingredient in the form of a granulate, for example, in admixture with fillers such as corn starch, binders and/or glidants such as talc or magnesium stearate and optionally stabilizers.
- the active ingredient is preferably dissolved or suspended in suitable liquids or wax-like substances such as fatty oils, paraffin oil or polyethylene glycols, it being possible also for stabilizers to be added.
- oral administration are, for example, syrups prepared in a customary manner that contain the active ingredient in, for example, suspended form in a concentration that provides a suitable single dose when administered.
- Suitable dosage forms for parenteral administration are sterile aqueous solutions of an active ingredient in water-soluble form, for example, a water-soluble salt, or sterile aqueous injection suspensions which contain substances increasing the viscosity, for example, sodium, carboxymethyl cellulose, sorbitol and/or dextran, and optionally stabilizers.
- the active ingredient, with or without adjuvants can also be in lyophilized form and brought into solution prior to parenteral administration by the addition of suitable solvents.
- the invention also relates to a method of treatment of pathological conditions in a mammal, especially human, which as has been described hereinabove, which method comprises administering, a therapeutically effective amount of a compound of the formula I or of a pharmaceutically acceptable salt thereof.
Abstract
A compound useful for treating subjects in need of therapy involving sigma receptors or for alleviation of affects resulting from drug abuse having the general formula I
in which R1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle such as, for example, radicals of optionally substituted piperidines, optionally substituted piperazines, optionally substituted tetrahydropyridines, optionally substituted azepanes, tertiary amines (cyclic or acyclic), isoindoline-1,3-dione, or optionally substituted tetrahydroisoquinolones (aromatically substituted): R2,3,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Y can be either CH, CH2, O, S, OCH2, N—R, N—Ar, C—R, C—Ar; Z can be either H, O, S, S—R or NR. R groups can be either H, aryls, alkyls, or cycloalkyls; “n” can be 1 to 5 carbons in length and stereoisomers, functional analogs, and pharmaceutically acceptable salts thereof and wherein the moiety bridging R1 and N can be optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene and where the alkylene group can include an inserted C3-C5 cycloalkyl group, aromatic and heterocyclic group.
Description
- This application claims the benefit of provisional patent application No. 60/956,249 filed Aug. 16, 2007, the entirety of which is incorporated by reference.
- The subject invention was made with government support under a research project supported by the United States Government in NIDA Grant Numbers DA023205, DA011979, DA013978 and NCRR P20 RR021929 and the government has certain rights to this invention.
- The present invention relates to the field of compounds which are sigma receptor ligands and methods of use thereof as sigma receptor ligands.
- Sigma receptors (a) have received much attention from the drug discovery field due to their possible involvement in schizophrenia, regulation of motor behavior, convulsions, anxiety, and the psychostimulant effects of drugs of abuse including cocaine, methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA).1,2 In addition to a host of neurological and psychiatric areas of interest, sigma receptors are promising drug development targets for, ontological, immunological, cardiovascular, opthalmological, developmental, gastrointestinal and metabolic disorders as well as those affecting the endocrine system. They are structurally unique proteins that are distinct from classical G protein-coupled receptors, ionotropic receptors, or receptor tyrosine kinases. With two subtypes currently known, they modulate cell survival and excitability, and subserve many critical functions in the body. Endogenous ligands for these receptors are unknown, though current clues point to neurosteroids.3
- The two subtypes, σ-1 and σ-2, were delineated by studies examining their respective molecular weights, distribution in tissue and drug selectivity profiles. The 223 amino acid σ-1 protein with two transmembrane spanning regions has been purified and cloned from several animal species including mouse, rat, guinea pig, and human.4-8 To date, the σ-1 receptor is well studied and known because of the receptor sequence information and availability of selective σ-1 ligands. But, the protein corresponding to σ-2 sites has not yet been cloned. Also, σ-2 receptor-selective ligands are less common, with tritiated DTG (1,3-di(2-tolyl)guanidine) being accepted as a radioligand in the presence of (+)-pentazocine (to block binding to σ-1 sites). Due to the lack of availability of detailed protein structural information and truly selective σ-2 ligands, the pharmacological characterization of the σ-2 subtype has been very limited. There is clearly a need for a selective σ-2 ligand which can not only act as a probe to explore unknown biochemical mechanisms, but also be used as a radioligand in σ-2 receptor binding assays.
- The abuse of drugs is a serious social, economic and health problem worldwide. Some of the opiates, cocaine, amphetamines and phencyclidine (PCP) are the drugs of abuse with significant affinities for a receptors. Current treatments for drugs of abuse are limited and there is a need to develop novel and effective agents to combat this problem.
- Cocaine use and abuse has been reported as early as the late 1500s.9 The historical use has been associated with the chewing of leaves from the Erythroxylon coca bush, from which cocaine was isolated in 1860,10 to eliminate fatigue in workers. Indeed, cocaine is a powerful and addictive psychostimulant. Cocaine abuse is widespread and is responsible for more serious intoxications and deaths than any other illicit drug. However, the invigorating effects of cocaine have caused it to become a major recreational drug of abuse throughout the world with an estimated 13 million people using the drug. In 2004, 34.2 million Americans aged 12 and over reported lifetime use of cocaine with approximately 5.6 million reporting annual use and an estimated 2 million reporting current use of the drug. In 2004 alone, there were an estimated 1 million new users of cocaine amounting to 2,700 per day. Despite a decline between 2002 and 2003 which is thought to potentially be due to increases in usage of other stimulants such as methamphetamine, data from the National Survey on Drug Use and Health showed near a 70% increase in the number of people receiving treatment for cocaine addiction from 276,000 in 2003 to 466,000 in 2004.11
- Currently, there are no approved medications to treat cocaine abuse or addiction. An effective strategy used to develop an anti-cocaine agent was the development of antagonists that compete with cocaine for its target proteins. For years, treatment approaches have targeted the dopaminergic system which is known to be involved in the actions and rewards of cocaine use. Many compounds were generated and tested that targeted the dopamine transporter which was identified as a primary site of action of cocaine. These compounds were met with very limited success as many of them just substituted for cocaine.12 After many years of investigation at the dopamine transporter as well as the dopamine receptors, researchers have been challenged to envision novel mechanisms that may afford new therapeutic interventions for cocaine addiction.
- Although many other mechanisms are under investigation, the a receptor system has been demonstrated and validated as a legitimate target for the attenuation of cocaine effects. The ability of cocaine to bind to the sigma receptors was discovered and first documented in 1988.13 It was reported that cocaine had micromolar affinity to the sigma receptor, and this interaction corresponded to micromolar levels that were achievable by cocaine in the body.14 Additional studies have indicated that reducing brain sigma receptor levels with antisense oligonucleotides attenuates the convulsive and locomotor stimulant actions of cocaine. Synthetic small molecule antagonists for sigma receptors have also been shown to mitigate the actions of cocaine in animal models. From prior work, the role of the σ-1 subtype has been clearly linked to the actions of cocaine. However, the role of the σ-2 receptor has been suggested, but is less clear due to the lack of truly selective ligands for this subtype.
- The present invention relates to compounds useful as sigma receptors of the following formula I:
- Wherein R1 can be an optionally substituted nitrogen-containing heterocycle radical such as, for example, radicals of optionally substituted piperidines, optionally substituted piperazines, optionally substituted tetrahydropyridines, optionally substituted azepanes, tertiary amines (cyclic or acyclic), isoindoline-1,3-dione, or optionally substituted tetrahydroisoquinolones (aromatically substituted): R2,3,4,5,6 can each independently be any one or combinations of the following moieties, such as, for example, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate anilino (unsubstituted or substituted), halogens (such as fluorine, chlorine, bromide and iodine), ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylenic, deuterium, or tritium; Y can be either CH, CH2, O, S, OCH2, N—R, N—Ar, C—R, C—Ar where Ar is an optionally substituted aryl. Z can be either H, O, S, S—R or NR. R groups can be either H, aryls, alkyls, or cycloalkyls. “n” can be 1 to 5 carbons in length and stereoisomers, analogs, and pharmaceutically acceptable salts thereof as well as compositions comprising said compounds. The moiety bridging R1 and N in the formula I can be an optionally substituted C1-C6 alkylene, C1-C6 alkenylene or C1-C6 alkynylene group wherein the alkylene group can have inserted into its chain a C3-C5 cycloalkyl group, aromatic, and heterocyclic group.
- FIG. 1—SN79 attenuates the convulsive effects of cocaine (***P<0.005)
- FIG. 2—SN79 pretreatment attenuates cocaine-induced locomotor activity (*P<0.05, **P<0.01)
- FIG. 3—SN79 pretreatment attenuates the development of cocaine-induced sensitization (*P<0.05, #P<0.05)
- FIG. 4—SN79 pretreatment attenuates the expression of cocaine-induced sensitization (**P<0.05 vs sensitized, ##P<0.05 vs acute cocaine)
- FIG. 5—CM156 attenuates the convulsive effects of cocaine (***P<0.005)
- FIG. 6—CM156 pretreatment attenuates cocaine-induced locomotor activity (*P<0.05)
- FIG. 7—CM156 pretreatment attenuates the expression of cocaine-induced sensitization (*P<0.05 vs sensitized, #P<0.05 vs acute cocaine)
- FIG. 8—CM156 pretreatment attenuates methamphetamine-induced locomotor activity (#P<0.05)
- FIG. 9—CM156 pretreatment attenuates methamphetamine-induced dopamine depletions (**P<0.05, ##P<0.05)
- The generic structure of Formula I encompasses a diverse range of heterocycles. Embodiments within this genus, for example, include 2(3H)-benzoxazolone (Y=O, Z=O) and 2(3H)-benzothiazolone (Y=S, Z=O) compounds and the sigma receptor affinity shown by these heterocycles. The 2(3H)-benzoxazolone (BOA) and its bioisosteric surrogate 2(3H)-benzothiazolone (BTA) heterocycle is a bicyclic ring system which promotes high versatility in organic synthesis involving N-substitution (either N-alkylation or N-acylation) and aromatic ring electrophilic substitution reactions.
- The present invention relates to compounds having the general formula I
- wherein R1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle or a radical of an optionally substituted cyclic or acyclic tertiary amine, or isoindoline-1,3-dioneR2,3,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanates, isocyanates, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Y can be either CH, CH2, O, S, OCH2, N—R, N—Ar, C—R, C—Ar; Z can be either H, O, S, S—R or NR. R groups can be either H, aryls, alkyls, or cycloalkyls; “n” can be 1 to 5 carbons in length and stereoisomers, functional analogs, and pharmaceutically acceptable salts thereof and wherein the moiety bridging R1 and N can be optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene and where the alkylene group can include an inserted C3-C5 cycloalkyl group, aromatic and heterocycle group.
- The optionally substituted N-containing heterocyclic radical can be for example optionally substituted piperidine, optionally substituted tetrahydropiperidine, optionally substituted piperazine, optionally substituted tetrahydropyridine, optionally substituted azepanes or optionally substituted tetrahydroisoquinoline in which the optional substituents are on the aromatic moiety.
- Exemplary compounds of the invention can be the general formulae II, III, IV, V and VI in which n=1-5:
- Other exemplary compounds of the invention are compounds where Y=O and Z=O; or Y=S and Z=S; or where Y=CH2 or Y=CH.
- R1 for example is optionally substituted
- As used herein, the term “lower” refers to a group having between one and six carbons.
- As used herein, the term “alkyl” refers to a straight or branched chain hydrocarbon having from one to ten carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, azido, isothiocyanate, isocyanate, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such an “alkyl” group may contain one or more O, S, S(O), or S(O)2 atoms. Examples of “alkyl” as used herein include, but are not limited to, methyl, n-butyl, t-butyl, n-pentyl, isobutyl, and isopropyl, and the like.
- As used herein, the term “alkylene” refers to a straight or branched chain divalent hydrocarbon radical having from one to ten carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such an “alkylene” group may contain one or more O, S, S(O), or S(O)2 atoms. Examples of “alkylene” as used herein include, but are not limited to, methylene, ethylene, and the like.
- As used herein, the term “alkenyl” refers to a hydrocarbon radical having from two to ten carbons and at least one carbon-carbon double bond, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such an “alkenyl” group may contain one or more O, S, S(O), or S(O)2 atoms.
- As used herein, the term “alkenylene” refers to a straight or branched chain divalent hydrocarbon radical having from two to ten carbon atoms and one or more carbon-carbon double bonds, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such an “alkenylene” group may contain one or more O, S, S(O), or S(O)2 atoms. Examples of “alkenylene” as used herein include, but are not limited to, ethene-1,2-diyl, propene-1,3-diyl, methylene-1,1-diyl, and the like.
- As used herein, the term “alkynyl” refers to a hydrocarbon radical having from two to ten carbons and at least one carbon-carbon triple bond, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such an “alkynyl” group may contain one or more O, S, S(O), or S(O)2 atoms.
- As used herein, the term “alkynylene” refers to a straight or branched
chain 5 divalent hydrocarbon radical having from two to ten carbon atoms and one or more carbon-carbon triple bonds, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such an “alkynylene” group may contain one or more O, S, S(O), or S(O)2 atoms. Examples of “alkynylene” as used herein include, but are not limited to, ethyne-1,2-diyl, propyne-1,3-diyl, and the like. - As used herein, “cycloalkyl” refers to an alicyclic hydrocarbon group optionally possessing one or more degrees of unsaturation, having from three to twelve carbon atoms, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. “Cycloalkyl” includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, and the like.
- As used herein, the term “cycloalkylene” refers to a non-aromatic alicyclic divalent hydrocarbon radical having from three to twelve carbon atoms and optionally possessing one or more degrees of unsaturation, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of “cycloalkylene” as used herein include, but are not limited to, cyclopropyl-1,1-diyl, cyclopropyl-1,2-diyl, cyclobutyl-1,2-diyl, cyclopentyl-1,3-diyl, cyclohexyl-1,4-diyl, cycloheptyl-1,4-diyl, or cyclooctyl-1,5-diyl, and the like.
- As used herein, the term “heterocyclic” or the term “heterocyclyl” refers to a three to twelve-membered heterocyclic ring optionally possessing one or more degrees of unsaturation, containing one or more heteroatomic substitutions selected from S, SO, SO2, O, or N, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such a ring may be optionally fused to one or more of another “heterocyclic” ring(s) or cycloalkyl ring(s). Examples of “heterocyclic” include, but are not limited to, tetrahydrofuran, 1,4-dioxane, 1,3-dioxane, piperidine, pyrrolidine, morpholine, piperazine, tetrahydropyridine, hexagydroazepine and the like.
- As used herein, the term “heterocyclyl containing at least one basic nitrogen atom” refers to a “heterocyclic” or “heterocyclyl” group as defined above, wherein said heterocyclyl group contains at least one nitrogen atom flanked by 20 hydrogen, alkyl, alkylene, or alkylyne groups, wherein said alkyl and/or alkylene groups are not substituted by oxo. Examples of “heterocyclyl containing at least one basic nitrogen atom” include, but are not limited to, piperazine-2-yl, pyrrolidine-2-yl, azepine-4-yl,
- and the like
- As used herein, the term “heterocyclylene” refers to a three to twelve-membered heterocyclic ring diradical optionally having one or more degrees of unsaturation containing one or more heteroatoms selected from S, SO, SO2, O, or N, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Such a ring may be optionally fused to one or more benzene rings or to one or more of another “heterocyclic” rings or cycloalkyl rings. Examples of “heterocyclylene” include, but are not limited to, tetrahydrofuran-2,5-diyl, morpholine-2,3-diyl, pyran-2,4-diyl, 1,4-dioxane-2,3-diyl, 1,3-dioxane-2,4-diyl, piperidine-2,4-diyl, piperidine-1,4-diyl, pyrrolidine-1,3-diyl, morpholine-2,4-diyl, piperazine-1,4-diyl, and the like.
- As used herein, the term “aryl” refers to a benzene ring or to an optionally substituted benzene ring system fused to one or more optionally substituted benzene rings, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy optionally substituted by acyl, mercapto, azido, isothiocyanate, isocyanate, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower periluoroalkyl, multiple degrees of substitution being allowed. Examples of aryl include, but are not limited to, phenyl, 2-naphthyl, 1-naphthyl, 1-anthracenyl, and the like.
- As used herein, the term “arylene” refers to a benzene ring diradical or to a benzene ring system diradical fused to one or more optionally substituted benzene rings, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. Examples of “arylene” include, but are not limited to, benzene-1,4-diyl, naphthalene-1,8-diyl, and the like.
- As used herein, the term “heteroaryl” refers to a five- to seven-membered aromatic ring, or to a polycyclic heterocyclic aromatic ring, containing one or more nitrogen, oxygen, or sulfur heteroatoms, where N-oxides and sulfur monoxides and sulfur dioxides are permissible heteroaromatic substitutions, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower perfluoroalkyl, multiple degrees of substitution being allowed. For polycyclic aromatic ring systems, one or more of the rings may contain one or more heteroatoms. Examples of “heteroaryl” used herein are furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, quinazoline, benzofuran, benzothiophene, indole, and indazole, and the like.
- As used herein, the term “heteroarylene” refers to a five- to seven-membered aromatic ring diradical, or to a polycyclic heterocyclic aromatic ring diradical, containing one or more nitrogen, oxygen, or sulfur heteroatoms, where N-oxides and sulfur monoxides and sulfur dioxides are permissible heteroaromatic substitutions, optionally substituted with substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfanyl, lower alkylsulfenyl, lower alkylsulfonyl, oxo, hydroxy, mercapto, amino optionally substituted by alkyl, carboxy, tetrazolyl, carbamoyl optionally substituted by alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, silyloxy optionally substituted by alkoxy, alkyl, or aryl, silyl optionally substituted by alkoxy, alkyl, or aryl, nitro, cyano, halogen, or lower periluoroalkyl, multiple degrees of substitution being allowed. For polycyclic aromatic ring system diradicals, one or more of the rings may contain one or more heteroatoms. Examples of “heteroarylene” used herein are furan-2,5-diyl, thiophene-2,4-diyl, 1,3,4-oxadiazole-2,5-diyl, 1,3,4-thiadiazole-2,5-diyl, 1,3-thiazole-2,4-diyl, 1,3-thiazole-2,5-diyl, pyridine-2,4-diyl, pyridine-2,3-diyl, pyridine-2,5-diyl, pyrimidine-2,4-diyl, quinoline-2,3-diyl, and the like.
- Initial efforts were focused on incorporating a good directionality by implying side-chains on a rigid template using conventional simple synthetic methodology. Exploring the effects of linker length between two hydrophobic regions for sigma receptor affinity led to the synthesis of 2 to 6 carbon linkers of 2(3H)-benzoxazolones ligands and 2(3H)-benzothiazolones compounds.
- The in vitro receptor binding affinities of the initial series of compounds of formulae II and III investigated in rat brain homogenates at σ-1 and σ-2 subtypes are summarized in tables 1 and 2.
-
TABLE 1 Initial series 2(3H)-benzoxazolones to explore the effects of linker length on sigma receptor affinity σ−1 σ−2 Compd. R1 R2−R5 n (Ki, nM) (Ki, nM) σ−1/σ−2 CM-129 H 2 6.90 ± 0.37 5.43 ± 0.78 1.3 CM-124 H 3 5.22 ± 1.11 8.74 ± 2.30 0.6 CM-121 H 4 11.3 ± 1.25 1.83 ± 0.17 6.2 CM-126 H 5 10.6 ± 2.52 5.89 ± 1.31 1.8 SN-48 H 6 4.60 ± 1.08 3.06 ± 0.45 1.5 -
TABLE 2 Initial series 2(3H)-benzoxazolones to explore the effects of linker length on sigma receptor affinity σ−1 σ−2 Compd. R1 R2−R5 n (Ki, nM) (Ki, nM) σ−1/σ−2 SN-97 H 2 6.66 ± 0.74 2.25 ± 0.37 2.1 SN-98 H 3 5.61 ± 0.74 3.05 ± 0.41 1.84 CM-145 H 4 4.17 ± 0.62 0.39 ± 0.06 10.63 SN-99 H 5 4.98 ± 0.42 2.44 ± 0.26 2.04 SN-102 H 6 6.55 ± 0.25 1.49 ± 0.18 4.40 - CM121 showed a six fold preference for the σ-2 subtype, suggesting that a four methylene spacer between the piperazine ring and the heterocycle may favor σ-2 affinity (Table 1, Scheme 1). During further SAR studies, compound CM170 was found to have an 11 fold preference for the σ-2 subtype, suggesting a 4-fluoropiperazine moiety may favor σ-2 affinity (Scheme 1). Additionally, CM142 having a 6-acetyl group in the 2(3H)-benzoxazolone heterocycle increased the preference for σ-2 receptors by 7 fold (Scheme 1).
- Interestingly, SN79 (Scheme 2) showed the highest selectivity (>16,500 fold) for the σ-2 subtype suggesting that a four methylene linker, a 6-acetyl group in the 2(3H)-benzoxazolone heterocycle and a 4-fluoropiperazine moiety favor σ-2 affinity over the σ-1 subtype.
- When tested on select non-sigma binding sites in rat brain homogenates (Table 3), compound SN79 exhibited weaker interactions, confirming preferential affinity for sigma receptors.
-
TABLE 3 Non-sigma binding affinity of SN79 Monoamine Other transporters Ki, nM Receptors Ki, nM DAT 2615 ± 62 Opioid >10,000 SERT 159 ± 15 NMDA >10,000 NET 177 ± 14 Dopamine (D2) >10,000 5-HT2 320 ± 16 - Compound SN79 was investigated for in vivo antagonizing effects in cocaine treated mice. Pretreatment of mice with SN79 led to a significant attenuation of cocaine-induced convulsions, locomotor activity and behavioral sensitization as seen in
FIGS. 1-4 . These data further demonstrate that compound SN79, acting through σ-2 receptors is able to significantly attenuate both the acute effects of cocaine as well as its chronic effects. - In addition to compounds exhibiting selectivity for the σ-2 receptor, compounds from this same series have demonstrated high affinity for both subtypes. Compound CM156 (Scheme 3), where the 2-oxo is replaced with a sulfur, demonstrated the highest affinity for both subtypes and was therefore examined in several non-sigma binding assays as shown in table 4. CM156 had much weaker affinity for other proteins of interest, confirming preferential affinity for sigma receptors.
-
TABLE 4 Non-sigma binding affinity of CM156 Monoamine Other transporters Ki, nM Receptors Ki, nM DAT 1175 ± 10 Opioid >10,000 SERT 1402 ± 152 NMDA >10,000 NET >10,000 Dopamine (D2) 1041 ± 9 5-HT2 1326 ± 159 - Compound CM156 was further investigated in vivo for antagonizing effects in cocaine treated mice. Pretreatment of mice with CM156 led to a significant attenuation of cocaine-induced convulsions, locomotor activity and behavioral sensitization as seen in
FIGS. 5-7 . Compound CM156 was additionally investigated for its ability to attenuate methamphetamine-induced locomotor stimulation and neurotoxicity in mice. As seen inFIGS. 8 and 9 , CM156 attenuated the locomotor stimulant effects of methamphetamine as well as the neurotoxic effects resulting from methamphetamine exposures. Together, these data demonstrate that CM156 with high affnitity for both a subtypes can mitigate a variety of drug-induced effects, both from cocaine and methamphetamine, in vivo. - The compounds of the present invention are for use as novel radioligands and agents for treatment of drugs of abuse including cocaine- and methamphetamine-induced abuse and toxicities.
- Compounds can be modified in several positions to investigate the effects around the core structure on σ-1 and σ-2 affinities and activities. It has been demonstrated that one can substitute the template molecule through several synthetic routes. These routes which can be easily performed utilizing parallel synthesis methodology, can be easily varied to obtain multiple novel ligands. Initial studies focused on exploring the following changes to the molecules through parallel methodologies: 1) varying the methylene spacer between the tertiary amine and heterocycle; 2) modifying substituents to the piperazine nitrogen above the template; 3) modifying the piperazine ring to substitute piperidines, tetrahydropyridines, azepanes and diazepines; 4) modifying the order of heteroatoms in the heterocycle portion of the molecule as well as the connectivity pattern; and 5) substitution on the benzo portion of the heterocycle to probe the space and physicochemical requirements of the a receptors.
- Compounds were analyzed after purification using standard techniques (NMR, IR, LC/MS, HPLC) and converted into hydrochloride salts for water solubility. Final purity of compounds were achieved through melting points and elemental analysis. When necessary, X-ray crystallography was performed.
- Syntheses of 2(3H)-benzoxazolones and 2(3H)-benzothiazolones were accomplished by multistep solution phase synthesis as shown
Scheme 4. Synthesis involved simple base-mediated alkylation and Friedel-Craft's alkylation reactions. - σ Receptor Assays
- Compounds were evaluated for σ-1 and σ-2 binding in rat brain homogenates. Twelve concentrations of each test ligand (0.001-1,000 nM) were incubated for 120 min at 25° C. in 50 mM Tris-HCl, pH 8.0 with 500 μg membrane protein, and 5 nM [3H](+)-pentnzocine (for σ1 assays) or 3 nM [3H]DTG plus 300 nM (+)-pentazocine (for σ2 assays); non-specific binding was determined in the presence of 10 μM haloperidol. The assays were terminated with ice-cold 10 mM Tris-HCl, pH 8.0, followed by two washes through glass fiber filters that were pre-soaked for at least 30 min in 0.5% polyethyleneimine.
- Non-σ Assays
- Compounds were tested at various non-σ target sites to evaluate selectivity because cocaine interacts with these sites (dopamine, serotonin and norepinephrine transporters) or historic “sigma” ligands interact with them (opioid, NMDA, dopamine D2, 5-HT2 receptors). The compounds were tested in competition binding assays using rat brain homogenates as previously published. Briefly, the radioligands to label the sites of interest and compounds to define non-specific binding were as follows: dopamine transporters (0.5 nM [3H]WIN35,428, 50 μM cocaine), serotonin transporters (0.2 nM [3H]paroxetine, 1.5 μM imipramine), norepinephrine transporters (0.5 nM [3H]nisoxetine, 4 μM desipramine), opioid receptors (2 nM [3H]bremazocine, 10 μM levollorphan), NMDA receptors (5 nM [3H]TCP, 10 μM cyclazocine), dopamine D2 receptors (5 nM [3H](+)-sulpiride, 1 μM haloperidol), and 5-HT2 receptors (2 nM [3H]ketanserin, 1 μM mianserin). The results were reported as Ki in nM. If after three independent replications of the assay, the 10,000 nM concentration of the compound did not display at least 30% inhibition of the radioligand, the affinity of the compound was reported as >10,000 nM.
- Cocaine-Induced Convulsions
- Male, Swiss Webster mice were pretreated (i.p.) with saline or compound (0.1-10 mg/kg), then challenged 15 min later with a convulsive dose of cocaine (70 mg/kg, i.p.). Mice were observed for the next 30 min for convulsions, which were defined as a loss of righting reflexes for at least 5 sec combined with the presence of clonic limb movements or popcorn jumping. Fisher's exact test was used to determine whether the effect produced by pretreatment with a particular drug dose differed significantly from pretreatment with the saline control.
- Cocaine-Induced Locomotor Activity
- Male, Swiss Webster mice were acclimated to the treatment room and then to the chambers of the automated activity monitoring system (San Diego Instruments, San Diego, Calif.). They were injected (i.p.) with saline or compound (0.1-20 mg/kg), then challenged 15 min later with cocaine (20 mg/kg, i.p.) or saline (i.p). The total locomotor activity (ambulatory, fine and rearing movements) of the mice was recorded for the next 30 min as the number of disruptions made by them in the 16×16 photobeam grid of their testing chamber.
- Development of Sensitization
- Male, Swiss Webster mice were acclimated as detailed above. For five consecutive days (Days 1-5), the mice were pretreated (i.p.) with saline or compound (0.1-20 mg/kg), then challenged 15 min later with cocaine (10 mg/kg, i.p.) or saline (i.p.). The total locomotor activity (ambulatory, fine and rearing movements) of the mice was recorded for the next 30 min as the number of disruptions made by them in the 16×16 photobeam grids of their testing chamber on each of the five days. A 10 day drug-free period followed. On Day 15, all of the mice were pre-administered (i.p.) saline followed by cocaine (10 mg/kg, i.p.), and locomotor activity quantified for the next 30 min.
- Expression of Sensitization
- Male, Swiss Webster mice were acclimated as detailed above. For five consecutive days (Days 1-5), the mice were pretreated (i.p) with saline, then challenged 15 min later with cocaine (10 mg/kg, i.p.). The total locomotor activity (ambulatory, fine and rearing movements) of the mice was recorded for the next 30 min. A 10 day drug free period followed and on Day 15, the mice were administered saline (i.p.) or compound (0.1-20 mg/kg), followed 15 min later with cocaine (10 mg/kg, i.p.). Locomotor activity was then recorded for the next 30 min.
- Methamphetamine-Induced Locomotor Activity
- Male, Swiss Webster mice were acclimated as detailed above. They were injected (i.p.) with saline or compound (0.1-20 mg/kg), then challenged 15 min later with methamphetamine (1 mg/kg, i.p.) or saline (i.p). The total locomotor activity (ambulatory, fine and rearing movements) of the mice was recorded for the next 30 min as the number of disruptions made by them in the 16×16 photobeam grids surrounding their testing chambers.
- Methamphetamine-Induced Dopamine Depletions
- Male, Swiss Webster mice were injected (i.p.) with saline or compound (0-20 mg/kg), followed 15 min later with either saline (− METH) or methamphetamine (5 mg/kg) at 2 hr intervals, a total of four times. Striatal dopamine levels were measured one week later.
- The following represents compounds which are within the scope of the invention and which were prepared and tested for activity. Also included are compounds which were prepared but not tested but which are expected to have activity similar to the prepared and tested compounds. Also included in the listing are compounds which can be prepared and which would be expected to have activities similar to those compounds which were prepared and tested.
-
Ki Compd. Structure (nM) SN-48 σ1 = 4.60 ± 1.08 σ2 = 3.06 ± 0.45 SN-55 σ1 = 34.12 ± 8.09 σ2 = 31.39 ± 6.87 SN-57 σ1 = 43.76 ± 6.12 σ2 = 29.29 ± 2.83 SN-60 σ1 = 12.06 ± 1.54 σ2 = 212.67 ± 11.81 SN-61 σ1 = 4.68 ± 1.37 σ2 = 107.1 ± 32.59 SN-71 σ1 = 114.74 ± 25.91 σ2 = 2342 ± 229.80 SN-72 σ1 = 3.33 ± 0.41 σ2 = 1810.66 ± 83.76 SN-78 σ1 = 88.31 ± 8.59 σ2 = 859.66 ± 86.59 SN-79 σ1 = >100,000 σ2 = 6.06 ± 0.74 SN-81 σ1 = 7.42 ± 3.21 σ2 = 224.56 ± 46.88 SN-97 σ1 = 4.66 ± 0.74 σ2 = 2.25 ± 0.37 SN-98 σ1 = 5.61 ± 0.74 σ2 = 3.05 ± 0.41 SN-99 σ1 = 4.98 ± 0.42 σ2 = 2.44 ± 0.26 SN-102 σ1 = 6.55 ± 0.25 σ2 = 1.49 ± 0.18 SN-123 SN-124 SN-125 SN-126 SN-127 SN-136 SN-137 SN-138 SN-139 SN-140 SN-147 SN-148 SN-150 SN-158 SN-167 SN-168 SN-169 SN-170 SN-196 SN-197 SN-198 SN-199 SN-203 SN-204 SN-205 SN-212 SN-213 SN-214 SN-XXX SN-XXX SN-XXX SN-XXX SN-XXX SN-XXX -
-
CMPD STRUCTURE Ki (nM) σ1 Ki (nM) σ2 CM 121 11.26 ± 1.25 1.83 ± 0.17 CM 124 5.22 ± 1.11 8.74 ± 2.30 CM 126 10.55 ± 2.52 5.89 ± 1.31 CM 129 6.90 ± 0.37 5.43 ± 0.78 CM 135 3.37 ± 0.28 3.77 ± 0.35 CM 138 7.87 ± 0.19 4.47 ± 0.42 CM 142 46.4 ± 8.06 7.04 ± 0.79 CM 145 4.17 ± 0.62 0.39 ± 0.06 CM 146 2.18 ± 0.14 2.56 ± 1.22 CM 152 19.3 ± 0.90 78.5 ± 39.6 CM 156 1.28 ± 0.38 0.55 ± 0.08 CM 159 4.44 ± 0.88 46.41 ± 12.61 CM 160 91.69 ± 11.52 2382.33 ± 142.94 CM 162 10.83 ± 1.00 46.75 ± 10.18 CM 165 2.40 ± 0.38 14.44 ± 3.09 CM 166 3.15 ± 0.37 92.71 ± 14.14 CM 167 259.07 ± 33.45 226.00 ± 17.50 CM 168 311.93 ± 33.22 128.10 ± 16.26 CM 169 25.44 ± 4.72 241.5 ± 28.98 CM 170 7.59 ± 0.08 0.70 ± 0.11 CM 171 0.94 ± 0.13 13.94 ± 2.86 CM 172 0.58 ± 0.22 17.22 ± 1.04 CM 174 4.04 ± 0.35 58.24 ± 11.48 CM 175 21.37 ± 3.68 616.33 ± 77.47 CM 176 1.43 ± 0.26 21.73 ± 2.79 CM 178 >10,000 >10,000 CM 179 1426.33 ± 185.09 2260 ± 96.08 CM 181 2.36 ± 0.38 8.83 ± 1.17 CM 182 14.08 ± 2.84 777.26 ± 72.47 CM 184 40.82 ± 6.21 10.41 ± 1.54 CM 188 11.11 ± 1.61 2.46 ± 0.18 CM 191 213.87 ± 55.33 77.37 ± 14.22 CM 295 74.31 ± 3.77 1.52 ± 0.64 CM 307 6.27 ± 0.78 6.61 ± 1.42 CM 308 9.11 ± 1.31 0.56 ± 0.12 CM 322 118.46 ± 48.37 1.67 ± 0.16 CM 325 5.04 ± 0.66 2.12 ± 0.75 CM 328 CM 329 CM 330 CM 338 169.8 ± 5.68 1.09 ± 0.03 CM 339 CM 341 3.28 ± 0.32 1.90 ± 0.16 CM 343 17.6 ± 0.82 38.13 ± 1.42 CM 347 CM 349 90.87 ± 12.30 22.55 ± 1.13 CM 350 1202 ± 73.89 83.33 ± 3.96 CM 353 CM 355 CM 356 27.82 ± 4.14 1.21 ± 0.20 CM 357 CM 360 73.25 ± 5.58 0.21 ± 0.020 CM 361 4713 ± 449.50 4.37 ± 0.33 CM 362 17.64 ± 3.34 2.79 ± 0.49 CM 365 5.94 ± 0.35 0.055 ± 0.0063 CM 366 22.55 ± 1.14 0.0061 ± 0.00096 CM 372 4.90 ± 1.70 0.77 ± 0.06 CM 373 CM 393 CM 394 CM 396 50.22 ± 7.59 2.57 ± 0.47 CM 397 414.83 ± 26.12 0.46 ± 0.03 CM 398 CM 401 2.89 ± 0.23 0.66 ± 0.08 CM 406 CM 407 CM 408 CM 418 CM 422 CM 423 CM 433 CM 435 CM 436 CM 442 CM 444 CM 449 CM 450 CM 454 CM 458 CM 459 CM 461 CM 464 CM 465 CM 466 CM 471 CM 483 CM 484 CM 485 CM 490 CM 491 CM 498 CM 500 CM 504 CM 528 CM 538 CM 539 CM 540 CM 563 CM 564 CM 566 CM 567 CM 569 CM 571 CM 572 CM 585 - The present invention comprises a method of treating a subject for alleviation of affects in the subject resulting from drug intake or drug abuse by the subject comprising administering to the subject a therapeutically effective amount of at least one compound according to the invention.
- The drug abuse or drug intake can result from methamphetamine intake or methamphetamine abuse by the subject or from cocaine abuse or cocaine intake by the subject.
- The present invention further comprises a method of treating a subject having a need for therapy involving sigma receptors comprising administering to the subject an effective amount of at least one compound of the present invention and additionally comprises treating a subject to prevent neurotoxic effects resulting from drug abuse or drug intake by the subject comprising administering to the subject a therapeutically effective amount of at least one compound according to the invention.
- The invention further comprises radioligand compositions comprising at least one compound according to the invention wherein at least one compound contains a radioactive element.
- Pharmaceutical compositions according to the invention are those which are suitable for enteral, such as oral, administration and for parenteral, such as subcutaneous, administration to warm-blooded animals, especially humans, and which contain the pharmacologically active substance on its own or together with a pharmaceutically acceptable carrier. The dosage of the active substance depends on the species of warm-blooded animal and on the age and individual condition, the illness to be treated and also on the mode of administration. Such dosage can be readily determined by those practicing in the relevant art area.
- The novel pharmaceutical preparations contain from approximately 10% to approximately 95%, and preferably from approximately 20% to approximately 90%, of the active substance. Pharmaceutical compositions according to the invention can, for example, be in unit dose form, such as dragees, tablets, capsules, suppositories or ampoules.
- The pharmaceutical compositions of the present invention are manufactured in a manner known per se, for example, by means of conventional mixing, granulating, confectioning, dissolving or lyophilizing processes. Pharmaceutical compositions for oral use can be obtained by combining the active substance with one or more solid carriers, if desired, granulating a resulting mixture and processing the mixture or granulate, if desired or necessary after the addition of suitable adjuncts, to form tablets or dragee cores. In so doing, they can also be incorporated into plastics carriers which release the active substances or allow them to diffuse in controlled amounts.
- Suitable carriers are especially fillers such as sugars, for example, lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, also binders such as starches, for example, corn, wheat, rice or potato starch, gelatine, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators such as the above-mentioned starches, also carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, alginic acid or a salt thereof such as sodium alginate. Adjuncts are especially flow-regulating and lubricating agents, for example, silica, talc, stearic acid or salts thereof such as magnesium or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings that are, if desired, resistant to gastric juice, there being used, inter alia, concentrated sugar solutions which optionally contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions in suitable organic solvents or solvent mixtures or, for the manufacture of coatings that are resistant to gastric juice, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Coloring substances or pigments can be added to the tablets or dragee coatings, for example for the purpose of identification or for indicating different doses of active substance.
- Other orally administrable pharmaceutical compositions are dry-filled capsules made of gelatin and also soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The dry-filled capsules may contain the active ingredient in the form of a granulate, for example, in admixture with fillers such as corn starch, binders and/or glidants such as talc or magnesium stearate and optionally stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquids or wax-like substances such as fatty oils, paraffin oil or polyethylene glycols, it being possible also for stabilizers to be added.
- Other forms of oral administration are, for example, syrups prepared in a customary manner that contain the active ingredient in, for example, suspended form in a concentration that provides a suitable single dose when administered.
- Further suitable dosage forms for parenteral administration are sterile aqueous solutions of an active ingredient in water-soluble form, for example, a water-soluble salt, or sterile aqueous injection suspensions which contain substances increasing the viscosity, for example, sodium, carboxymethyl cellulose, sorbitol and/or dextran, and optionally stabilizers. In addition, the active ingredient, with or without adjuvants, can also be in lyophilized form and brought into solution prior to parenteral administration by the addition of suitable solvents.
- The invention also relates to a method of treatment of pathological conditions in a mammal, especially human, which as has been described hereinabove, which method comprises administering, a therapeutically effective amount of a compound of the formula I or of a pharmaceutically acceptable salt thereof.
- The examples provided in the present application serve to illustrate the invention, but should not be construed as a limitation thereof.
-
- 1. Matsumoto, R. R. et. al. Eur. J. Pharmacol. 2001, 411, 261-273.
- 2. Maurice, T. et. al. Prog. Neuropsychopharmacol. Biol. Psychiatry 1997, 21, 69-102.
- 3. Sigma receptors: chemistry, cell biology and clinical implications. Edited by Rae R. Matsumoto, Wayne D. Bowen and Tsung Ping Su. New York, Springer 2007.
- 4. Hanner, M. et. al. Proc. Natl. Acad. Sci. USA. 1996, 93, 8072-8077.
- 5. Kekuda, R. Y., et. al. Biochem. Biophys. Res. Commun. 1996, 229, 553-558.
- 6. Seth, P. et. al. Biochem. Biophys. Res. Commun. 1997, 41, 535-540.
- 7. Seth, P. et. al. J. Neurochem. 1998, 70, 922-931.
- 8. Mei, J and Pasternak G W. Biochem Pharmacol. 2001, 62, 349-355
- 9. Perrine, D M (1996) The Chemistry of Mind-Altering Drugs. American Chemical Society. Washington, D.C.
- 10. Wohler, V. (1862) Fortsetzung der Untersuchungen uber die Coca and das Cocain. Justus Liebigs Annalen der Chemie 121: 372.
- 11. National Survey on Drug Use and Health—http://www.samhsa.gov
- 12. Carroll F I., Howell L L, Kuhar M J (1999) Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. 42: 2721-2736.
- 13. Sharkey J, Glen K A, Wolfe S, Kuhar M J. Cocaine binding at sigma receptors. Eur. J. Pharmacol. 1988, 149:171-174.
- 14. Mittleman R, Wetli C V. Death caused by recreational cocaine use: an update. J. Am. Med. Assoc. 1984, 252:1889-1893.
Claims (6)
1-34. (canceled)
35. A method of treating a subject for alleviation of effects in the subject resulting from drug intake or drug abuse by the subject comprising administering to the subject a therapeutically effective amount of at least one compound having the general formula I
wherein R1 can be an optionally substituted piperidine, an optionally substituted piperazine, an optionally substituted tetrahydropyridine, an optionally substituted azepane or an optionally substituted tetrahydroisoquinoline in which the optional substituents are on the aromatic moiety or an optionally substituted tetrahydropiperidine, or a radical of an optionally substituted cyclic or acyclic tertiary amine or isoindoline-1,3-dione: R2,3,4,5 can each independently be any one or combinations of the following moieties, hydrogen, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; wherein when R2,3,4,5 is a halogen, the halogen is fluorine, bromine or iodine “n” can be 1 to 5 carbons in length and wherein the moiety bridging R1 and N can be optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene with the exclusion of the following compounds:
and stereoisomers, or pharmaceutically acceptable salts thereof.
36. A method according to claim 35 wherein the drug abuse or drug intake results from methamphetamine intake or methamphetamine abuse by the subject.
37. A method according to claim 35 wherein the drug intake or drug intake results from cocaine abuse or cocaine intake by the subject.
38. A method of treating a subject having a need for therapy involving sigma receptors comprising administering to the subject an effective amount of at least one compound of claim 35 .
39. A method of treating a subject to prevent neurotoxic effects resulting from drug abuse or drug intake by the subject comprising administering to the subject a therapeutically effective amount of at least one compound having the general formula I
wherein R1 can be an optionally substituted piperidine, an optionally substituted piperazine, an optionally substituted tetrahydropyridine, an optionally substituted azepane or an optionally substituted tetrahydroisoquinoline in which the optional substituents are on the aromatic moiety or an optionally substituted tetrahydropiperidine, or a radical of an optionally substituted cyclic or acyclic tertiary amine or isoindoline-1,3-dione: R2,3,4,5 can each independently be any one or combinations of the following moieties, hydrogen, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; wherein when R2,3,4,5 is a halogen, the halogen is fluorine, bromine or iodine “n” can be 1 to 5 carbons in length and wherein the moiety bridging R1 and N can be optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene with the exclusion of the following compounds:
and stereoisomers, or pharmaceutically acceptable salts thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/321,100 US20140315919A1 (en) | 2007-08-16 | 2014-07-01 | Highly selective sigma receptor ligands |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95624907P | 2007-08-16 | 2007-08-16 | |
PCT/US2008/073478 WO2009026227A2 (en) | 2007-08-16 | 2008-08-18 | Highly selective sigma receptor ligands |
US12/673,486 US8809381B2 (en) | 2007-08-16 | 2008-08-18 | Highly selective sigma receptor ligands |
US14/321,100 US20140315919A1 (en) | 2007-08-16 | 2014-07-01 | Highly selective sigma receptor ligands |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/073478 Division WO2009026227A2 (en) | 2007-08-16 | 2008-08-18 | Highly selective sigma receptor ligands |
US12/673,486 Division US8809381B2 (en) | 2007-08-16 | 2008-08-18 | Highly selective sigma receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140315919A1 true US20140315919A1 (en) | 2014-10-23 |
Family
ID=40378945
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/673,486 Active 2030-01-10 US8809381B2 (en) | 2007-08-16 | 2008-08-18 | Highly selective sigma receptor ligands |
US14/321,100 Abandoned US20140315919A1 (en) | 2007-08-16 | 2014-07-01 | Highly selective sigma receptor ligands |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/673,486 Active 2030-01-10 US8809381B2 (en) | 2007-08-16 | 2008-08-18 | Highly selective sigma receptor ligands |
Country Status (2)
Country | Link |
---|---|
US (2) | US8809381B2 (en) |
WO (1) | WO2009026227A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2941634C (en) * | 2014-03-04 | 2023-04-18 | The University Of Mississippi | Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders |
CN115286616A (en) * | 2022-07-27 | 2022-11-04 | 北京师范大学 | Tetrahydroisoquinoline and isoindoline compound capable of binding sigma-2 receptor, preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2609645A1 (en) * | 1976-03-09 | 1977-09-15 | Boehringer Sohn Ingelheim | AMINOALKYLHETEROCYCLES |
GB8615562D0 (en) * | 1986-06-25 | 1986-07-30 | Maggioni Farma | Aminoalcohols |
WO1987002359A1 (en) * | 1985-10-14 | 1987-04-23 | Maggioni-Winthrop S.P.A. | Dihydrobenzothiophene and thiochromane aminoalcohols |
ATE291015T1 (en) * | 1997-11-05 | 2005-04-15 | Mitsubishi Chem Corp | ALKYLAMINO DERIVATIVES |
-
2008
- 2008-08-18 US US12/673,486 patent/US8809381B2/en active Active
- 2008-08-18 WO PCT/US2008/073478 patent/WO2009026227A2/en active Application Filing
-
2014
- 2014-07-01 US US14/321,100 patent/US20140315919A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
Xu et al. "A Novel Substituted Piperazine, CM156, Attenuates the Stimulant and Toxic Effects of Cocaine in Mice" The Journal of Pharmacology and Experimental Therapeutics, published January 25, 2010, vol. 33, no. 2, pp. 491-500. * |
Also Published As
Publication number | Publication date |
---|---|
WO2009026227A2 (en) | 2009-02-26 |
US20110195955A1 (en) | 2011-08-11 |
WO2009026227A3 (en) | 2009-04-09 |
US8809381B2 (en) | 2014-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150018339A1 (en) | Highly selective sigma receptor ligands | |
FI114475B (en) | Process for the preparation of novel therapeutically useful quinuclidine derivatives | |
EP2498599B1 (en) | Analgesic that binds filamin a | |
TW200900403A (en) | Pyrimidinone derivatives and methods of use thereof | |
CA2679809A1 (en) | Benzimidazole derivatives and methods of use thereof | |
US9963450B2 (en) | A3 adenosine receptor agonists | |
US20100324017A1 (en) | Acylguanidine derivative | |
AU2001295436C1 (en) | Novel azabicyclooctene derivatives and their medical use | |
US20220185798A1 (en) | Dopamine d3 receptor selective antagonists/partial agonists; method of making; and use thereof | |
US8653068B2 (en) | Filamin A binding anti-inflammatory and analgesic | |
RU2198175C2 (en) | Derivatives of 1,2,3,4-tetrahydrobenzofuro[3,2-c]-pyridine, methods of their synthesis and compositions based on thereof | |
US20200024285A1 (en) | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | |
KR101960107B1 (en) | 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain | |
US20140315919A1 (en) | Highly selective sigma receptor ligands | |
US8614324B2 (en) | Filamin A binding anti-inflammatory and analgesic | |
US5049637A (en) | 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino-[1,2-a]azepino derivatives and 10-aza, 10-oxa and 10-thia analogues | |
SK9398A3 (en) | (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2- -methoxy-6-methylamino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same | |
US20130109711A1 (en) | Novel compounds | |
US9604926B2 (en) | Highly selective sigma receptor radioligands | |
US20160251374A1 (en) | Filamin a binding anti-inflammatory and analgesic | |
US8580809B2 (en) | Filamin A-binding anti-inflammatory analgesic | |
US8580808B2 (en) | Filamin A-binding anti-inflammatory analgesic | |
Imanishi et al. | New thiazole derivatives as potent and selective 5-hydroxytriptamine 3 (5-HT3) receptor agonists for the treatment of constipation | |
KR20080041733A (en) | Thiomorpholine compound and process for preparing the same | |
US20200291000A1 (en) | Dopamine d3 receptor selective antagonists/partial agonists; method of making; and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |